Maternal medical history, psychosocial factors, and birth outcomes by Haviland, Miriam
Boston University
OpenBU http://open.bu.edu
Theses & Dissertations Boston University Theses & Dissertations
2020
Maternal medical history,
psychosocial factors, and birth
outcomes
https://hdl.handle.net/2144/39307
Boston University
BOSTON UNIVERSITY 
 
SCHOOL OF PUBLIC HEALTH  
 
 
 
 
 
Dissertation 
 
 
 
 
 
MATERNAL MEDICAL HISTORY, PSYCHOSOCIAL FACTORS, 
 
AND BIRTH OUTCOMES  
 
 
 
 
by 
 
 
 
 
MIRIAM JOAN HAVILAND 
 
B.A., Johns Hopkins University, 2010 
M.S.P.H., Johns Hopkins University, 2013 
 
 
 
 
 
 
Submitted in partial fulfillment of the 
 
requirements for the degree of 
 
Doctor of Philosophy 
 
2020 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
© 2020 
MIRIAM JOAN HAVILAND 
All rights reserved 
Approved by 
 
 
 
 
 
 
First Reader   
 Lauren A. Wise, Sc.D. 
 Professor of Epidemiology 
 
 
 
 
Second Reader   
 Matthew P. Fox, D.Sc. 
 Professor of Epidemiology 
 Professor of Global Health 
 
 
 
 
Third Reader   
 Michele R. Hacker, Sc.D. 
 Vice Chair for Research 
 Department of Obstetrics and Gynecology 
 Beth Israel Deaconess Medical Center 
 Associate Professor of Obstetrics, Gynecology and Reproductive 
Biology 
 Harvard Medical School 
 Associate Professor of Epidemiology 
 Harvard T.H. Chan School of Public Health 
 
 
 
 
Fourth Reader   
 Yael I. Nillni, Ph.D. 
 Assistant Professor of Psychiatry 
 Boston University, School of Medicine 
 
  
  iv 
ACKNOWLEDGMENTS 
I would first and foremost like to thank my dissertation committee, Drs. Lauren Wise, 
Matthew Fox, Michele Hacker, and Yael Nillni for their time and guidance throughout 
this process. I have been incredibly privileged to have had the opportunity to learn from 
them over the past few years. I would also like to thank Dr. Hacker and Dr. Heather 
Burris for introducing me to epidemiologic research and providing me with the 
mentorship and support that led me to become an epidemiologist.  
 
I am extremely grateful for the friendship and support I have received from my fellow 
students, especially my cohort—Laura Sampson, Jane Seymour, Lynsie Ranker, Daina 
Esposito, and Takara Stanley. I could not have asked for a better group of women to learn 
from. I would also like to thank the Boston University Department of Epidemiology for 
allowing me to finish my degree remotely and for their support throughout my training. 
 
This dissertation would not have been possible without the unending love and support I 
have received from my parents throughout my life. From an early age my mother inspired 
in me a love of learning, while my father taught me the analytic skills necessary to be 
thoughtful epidemiologist. They also taught me to be disciplined, to work hard for the 
things that I want in life, and to learn from my mistakes. Without them I would not be 
where I am today.  
 
  v 
Finally, I would like to thank my husband for being my scientist role model and partner 
in all things.  
  vi 
MATERNAL MEDICAL HISTORY, PSYCHOSOCIAL FACTORS, 
AND BIRTH OUTCOMES 
MIRIAM JOAN HAVILAND 
 
Boston University School of Public Health, 2020 
 
Major Professor: Lauren A. Wise, Sc.D., Professor of Epidemiology 
 
ABSTRACT 
Major depressive disorder, anxiety, and psychological stress are common co-occurring 
morbidities in pregnancy. Psychotropic medications are commonly used to treat these 
conditions, though many women discontinue use in pregnancy due to concerns for 
adverse pregnancy outcomes. Prior investigations into the effect of psychotropic 
medications on preterm delivery may be prone to confounding by indication. In the first 
study of this dissertation, we compared mean gestational age at delivery between women 
who used psychotropic medications during pregnancy and women who never used 
medications, stratifying by severity of preconception depressive symptoms and perceived 
stress (measured before and during pregnancy). We used data from the Boston University 
Pregnancy Study Online (PRESTO), an ongoing prospective cohort study of pregnancy 
planners. We found that women who used medications during pregnancy delivered 
slightly earlier (37.2 weeks; 95% CI: 36.4, 37.9) than women who never used 
medications (38.1 weeks; 95% CI: 37.5, 38.6). We observed these associations among 
women with both high and low levels of depressive symptoms and perceived stress. Our 
results suggest that psychotropic medication use during pregnancy may be associated 
with slightly shorter gestations.  
  vii 
Mental health symptoms (depression and anxiety), stress, and low psychosocial resources 
(social support and resilience) are associated with preterm delivery. Many of these 
psychosocial factors tend to co-occur and women who experience more than one of these 
factors are more likely to deliver preterm than women who experience only one. 
Understanding what combinations of adverse psychosocial factors women experience 
during pregnancy may help clinicians more effectively identify women at risk of preterm 
delivery. In our second study, we identified three latent classes of adverse psychosocial 
factors (few, some, and many factors) using data from Spontaneous Prematurity and 
Epigenetics of the Cervix (SPEC), a prospective cohort study of pregnant women at Beth 
Israel Deaconess Medical Center. Participants with both some (RR: 1.50; 95% CI: 0.86, 
2.62) and many adverse psychosocial factors (RR: 1.29; 95% CI: 0.36, 5.00) were more 
likely to deliver preterm than participants with few factors, though these associations 
were imprecisely estimated. Our findings suggest that screening for multiple adverse 
psychosocial factors may help providers better identify women at risk of preterm 
delivery. 
 
Despite advances in in vitro fertilization (IVF) technology, less than half of IVF cycles 
result in a pregnancy. These low pregnancy probabilities may be due to chromosomal 
nondisjunction, which causes nonviable aneuploid embryos that are naturally rejected by 
the body. Preimplantation genetic testing for aneuploidy (PGT-A) was developed to 
identify euploid embryos prior to implantation. Prior evaluations of PGT-A have 
produced mixed results, and may be prone to confounding by indication. In our third 
  viii 
study, we evaluated the effect of PGT-A on the cumulative incidence of live birth, 
controlling for important confounders using a propensity score for PGT-A. We found that 
women ≥38 years old who used PGT-A were more likely to have a live birth than women 
≥38 years old who did not use PGT-A (RR: 1.67; 95% CI: 1.31, 2.13). We also observed 
that PGT-A increased the likelihood of having a live birth among women 35-37 years old 
(RR: 1.27; 95% CI: 1.05, 1.54). Among women <35 years old, those who used PGT-A 
were no more likely to have a live birth than those who did not (RR: 0.91; 95% CI: 0.78, 
1.06). Our findings suggest that PGT-A may be beneficial for older women. 
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1.0 INTRODUCTION 
1.1 STUDIES 1 AND 2 
Each year, approximately 10% of infants in the United States (U.S.) are delivered preterm 
(<37 weeks’ gestation).1 Preterm delivery is associated with increased risks of neonatal 
morbidity and mortality, as well as neurodevelopmental disabilities in childhood and 
adulthood.2  Thus, identification of modifiable risk factors for preterm delivery could 
have important implications for medicine and public health. 
About one-third of preterm deliveries are attributable to medical indications, such as 
maternal infection and hypertension, while the remainder are considered “spontaneous” 
(preterm premature rupture of membranes or preterm labor).3–6 Premature activation of 
the maternal or fetal hypothalamic-pituitary-adrenal (HPA) axis is thought to be one of 
the possible causes of preterm delivery.4 Studies 1 and 2 focus on exposures that could 
plausibly influence preterm delivery via this mechanism.  
Mental health conditions (major depressive disorder and anxiety), and psychological 
stress are common co-occurring morbidities in pregnancy, with 15-25% of pregnant 
women in the U.S. experiencing at least one of these conditions.7–9 These conditions may 
increase the risk of preterm delivery by causing an increase in placental corticotrophin-
releasing hormone (CRH). CRH is a hypothalamic neuropeptide that helps regulate the 
activity of the HPA axis and the body’s physiologic response to stress.10 During 
pregnancy, CRH is also expressed in the placenta and placental membranes, and placental 
CRH plays a central role in the onset of labor. Women who deliver spontaneously 
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preterm have been shown to have both higher CRH throughout their pregnancy and a 
faster rate of CRH increase during pregnancy than women who deliver at term.11,12  
Psychotropic medications—such as antidepressants and anxiolytics—are commonly used 
to treat depression, anxiety, and stress.13 Many women continue to use psychotropic 
medications in pregnancy, as discontinuation of medications may increase the risk of 
relapse as well as adverse pregnancy outcomes.14 There is concern, however, that use of 
these medications during pregnancy may also increase the risk of adverse birth outcomes, 
although studies examining the association between psychotropic medication use and 
preterm delivery have produced mixed results.15-19 The effects observed in many of these 
studies may be due to confounding by indication as most have relied on population-based 
registries that rarely contain data on type and severity of underlying mental health 
conditions.17,18 In the first dissertation study, we used data from a cohort of North 
American pregnancy planners to evaluate the extent to which psychotropic medication 
use in pregnancy affects gestational age at delivery, and the degree to which the 
association is confounded by severity of preconception depressive symptoms or 
perceived stress (measured before and during pregnancy). 
 
Mental health symptoms, stress, and additional adverse psychosocial factors, such as low 
resilience and low social support, commonly co-occur in pregnancy, and experiencing 
multiple factors may further increase the risk of preterm delivery.20,21 By identifying 
groups of women who experience similar combinations of these factors, we may be able 
to better predict preterm delivery while also gaining information about which factors are 
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most prevalent among different groups of women. In the second dissertation study, we 
performed a latent class analysis in a cohort of pregnant women seeking care at a tertiary 
care center in Boston, Massachusetts to identify distinct clusters of psychosocial risk 
factors among pregnant women. 
1.2 STUDY 3 
Up to 15% of couples in the United States experience infertility, defined as the inability 
to conceive after at least one year of unprotected intercourse.22,23 The Centers for Disease 
Control and Prevention estimates that 12% of women aged 15-44 are infertile or have 
trouble carrying a pregnancy to term.24 Many of these women and couples utilize assisted 
reproductive technologies to help them conceive.       
 
In vitro fertilization (IVF) is an assisted reproductive technology where the sperm and 
oocyte are handled outside of the body in a laboratory and a fertilized embryo is 
transferred to the uterus.25 There are four steps to IVF: 1) ovulation induction, when a 
woman is given hormones to induce ovulation, 2) oocyte retrieval, 3) oocyte 
insemination, and 4) transfer of the embryo to the uterus.26 Today 1-2% of births in the 
U.S. each year are the result of IVF pregnancies.27  
 
Despite many advances in IVF technology over the past four decades, among women 
aged 18-40 years of age, only 25-40% of IVF cycles result in pregnancy.28 These low 
pregnancy probabilities are predominantly due to chromosomal nondisjunction that 
causes nonviable aneuploid embryos that are naturally rejected by the body.26,29 To 
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increase the probability of pregnancy and live birth among women undergoing IVF, 
preimplantation genetic testing for aneuploidy (PGT-A) can be used to identify euploid 
embryos prior to transfer.26,29 
 
Despite the promise of PGT-A, studies comparing the incidence of live birth from IVF 
cycles with PGT-A to those without are inconsistent.30,31 Conflicting results may be due 
to confounding by indication, as women whose embryos undergo PGT-A may be less 
fecund than other women due to factors such as advanced maternal age.  
 
Propensity scores can accurately estimate the treatment effect in situations where there is 
strong confounding by indication by isolating comparable exposed and unexposed 
subjects.32,33 In the third dissertation study, we utilized data from one of the largest 
providers of infertility treatment in the U.S. and a matched propensity score design to 
evaluate the effect of PGT-A on the cumulative incidence of live birth. 
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2.0 PSYCHOTROPIC MEDICATION USE DURING PREGNANCY AND 
GESTATIONAL AGE AT DELIVERY 
 
2.1 BACKGROUND 
Major depressive disorder, anxiety, and psychological stress are common co-occurring 
morbidities in pregnancy, with 15-25% of pregnant women in the U.S. experiencing at 
least one condition.1–3 Some studies have shown a higher incidence of preterm delivery 
(<37 weeks’ gestation) among women with higher levels of depression4–6 or perceived 
stress.5  
 
Depression, anxiety, and stress may increase the risk of preterm delivery by causing an 
increase in placental corticotrophin-releasing hormone (CRH). CRH is a hypothalamic 
neuropeptide that helps regulate the activity of the hypothalamic pituitary adrenal axis 
and the physiologic response to stress.7 During pregnancy, CRH is also expressed in the 
placenta and placental membranes, and placental CRH may play a central role in the 
onset of labor. Women with spontaneous preterm deliveries have been shown to have 
both higher CRH throughout pregnancy and a faster rate of CRH increase during 
pregnancy than women who deliver at term.8,9 The use of psychotropic medications (e.g., 
antidepressants and anxiolytics) among women with depression, anxiety, or stress is of 
interest because many of these medications can cross the placental barrier.10 Women who 
use psychotropic medications during pregnancy have been shown to have higher levels of 
CRH than untreated women with depression.11 This increase in CRH may lead to preterm 
delivery.  
  
9 
 
Although psychotropic medications are commonly used to treat depression, anxiety, and 
stress,12 many women discontinue use of psychotropic medications during pregnancy due 
to concerns about teratogenicity and adverse pregnancy outcomes.13,14 Studies of the 
effect of psychotropic medications on preterm delivery have produced mixed results. 
Some studies indicate that use of psychotropic medications during pregnancy increases 
the risk of preterm delivery among depressed women15–17 while others report no 
additional risk.18,19 The majority of these studies have used data from population based 
registries.17,18  As information about the type and level of severity of the underlying 
mental health condition is not available in these registries, registry-based studies are 
prone to confounding by indication.  
 
We evaluated the extent to which psychotropic medication use during pregnancy is 
associated with gestational age at delivery, and to what degree any effects are confounded 
by severity of depressive symptoms and perceived stress.  
  
2.2 METHODS 
2.2.1 Study design 
Boston University Pregnancy Study Online (PRESTO) is a prospective preconception 
cohort study of female pregnancy planners and their male partners. Eligible participants 
are women aged 21-45 years who live in the U.S. and Canada, not using contraception or 
fertility treatments, and actively trying to conceive. Women complete online 
questionnaires at baseline and every eight weeks for up to 12 months or until reported 
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pregnancy, whichever comes first. Participants who conceive complete additional 
questionnaires during the first trimester (~8-12 weeks’ gestation) and third trimester (~32 
weeks’ gestation) of pregnancy. The baseline questionnaire ascertains current depressive 
symptoms, current perceived stress levels, as well as past and current use of medications 
to treat these conditions. Follow-up questionnaires update information about perceived 
stress and current use of psychotropic medication, though not depressive symptoms. 
Approximately six months after their reported due date, women complete a postpartum 
questionnaire that elicits data on birth characteristics, including gestational age at 
delivery and infant birth weight. Questionnaire data are linked with birth registry data in 
selected states (CA, FL, MA, MI, OH, PA, and TX) to obtain additional information on 
birth characteristics. This study was approved by the institutional review board at Boston 
University. 
 
2.2.2 Psychotropic medication use 
Data on participant use of psychotropic medications were collected on all questionnaires. 
Specifically, on the baseline questionnaire, participants reported: 1) ever use, 2) total 
years of use, 3) the names of the medications taken the longest and most recently, and 4) 
medication use in the past four weeks. Participants also reported use of medications 
within the past four weeks on the early and late pregnancy questionnaire. Finally, 
participants reported medication use by trimester (querying about each trimester 
individually) on the late pregnancy questionnaire). These questions were asked separately 
for medications taken for depression, anxiety/panic disorder, and other indications (e.g., 
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sleep disorders). In our cohort, the majority of women who used psychotropic 
medications during pregnancy used them throughout their entire pregnancy (Table 2.1), 
thus we categorized use of psychotropic medications as: 1) never use, 2) use before but 
not during pregnancy, 3) use before and during pregnancy, and 4) initiated use during 
pregnancy. We considered women to be users of psychotropic medications during 
pregnancy if they reported psychotropic medication use “within the past four weeks” on 
either the early or late pregnancy questionnaires, or if they reported use in any trimester 
on the late pregnancy questionnaire, regardless of indication for use.21 
 
2.2.3 Depressive symptoms and perceived stress 
Depressive symptoms were assessed at baseline using the 12-item Major Depression 
Inventory (MDI), which has been shown to have good sensitivity and specificity when 
screening for major depression.22,23 The MDI has been shown to have good internal 
consistency (Mokken analysis coefficient >0.40) and external validity when used among 
both psychiatric and non-psychiatric patients (r>0.70).24,25 This scale includes questions 
such as “Have you felt low in spirits or sad?” and “Have you felt that life isn’t worth 
living?”. Participants were asked to rate how often within the past two weeks they 
experienced each symptom. Response options were on a 6-point scale ranging from 0 (at 
no time) to 5 (all of the time). We used standard scoring criteria to calculate a total score 
for the MDI (range 0-60) and categories of depressive symptoms none/low (<20), mild 
(20-24), moderate (25-29), severe (≥30).26  
 
Perceived stress was assessed using the 10-item Perceived Stress Scale (PSS) on the 
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baseline and early pregnancy questionnaires.27 In validation studies conducted among 
community samples with at least an 8th grade education, the PSS has been shown to 
capture stress effectively during the previous 4-8 weeks.27–29 The PSS has been found to 
have good internal consistency (Cronbach alpha >0.70), test-retest reliability (r>0.70), 
and content validity (r>0.70).28 The PSS has not been validated among pregnant women, 
but it has been used in other pregnancy studies.5,30 The scale asks respondents how often 
they have had certain thoughts and feelings within the past month. Questions include “in 
the past month how often have you been upset because of something that happened 
unexpectedly?” and “In the last month how often have you felt that you were on top of 
things?”. Answers are on a 5-point scale ranging from 0 (never) to 4 (very often). We 
used standard scoring criteria to calculate a total score for the PSS (range 0-40). As there 
are no clinical cut points for the PSS, we categorized PSS scores based on the distribution 
in the analytic cohort (<15, 15-19, 20-24, ≥25).  
 
2.2.4 Outcome assessment 
Gestational age at delivery was ascertained from birth registries in selected states (CA, 
FL, MA, MI, OH, PA, and TX) and via self-report by participants on the postpartum 
questionnaire. When both sources of data were available, we used gestational age at 
delivery from the birth registry. Gestational age in birth registries is based on the 
“obstetric estimate,” which is determined by confirming the date of last menstrual period 
via early ultrasound.31 This method is considered superior to estimates based on last 
menstrual period alone.32–34   
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We considered women who delivered at <37 weeks as having a preterm delivery. 
Although women who reported a preterm delivery on the postpartum questionnaire were 
asked whether their delivery was spontaneous or medically-indicated, there were too few 
preterm births reported on this questionnaire (n=155) to evaluate the associations of 
interest by preterm birth subtype.  
 
2.2.5 Covariate assessment 
All covariate information was self-reported on the baseline questionnaire including: age 
at enrollment, weight, height, race/ethnicity, education, employment status, annual 
household income, gravidity, parity, marital status, history of preterm deliveries, history 
of infertility, smoking, alcohol intake, and self-reported clinical diagnoses of depression 
or anxiety/panic disorder before study entry. We calculated body mass index (BMI) by 
dividing weight (kg) by height (m)2. 
 
2.2.6 Statistical analyses 
Women who enrolled in PRESTO from the date of first enrollment (June 2013) through 
dataset closure (June 2019) and who reported a conception from June 2013 through 
March 2018 (to allow for 15 months of follow-up time for all participants) were eligible 
for inclusion in the analysis (n=3,539). We excluded women with multiple gestations 
(n=24). Although women can enroll in PRESTO multiple times, all participants 
experienced only one live birth during our study period (all women who enrolled multiple 
times experienced an early pregnancy loss during their first enrollment). 
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We used multiple imputation to impute missing exposure, covariate, and outcome data.35  
We generated five imputation data sets using a Markov chain Monte Carlo method.36  All 
women in our analytic sample had either exposure or outcome data available prior to 
imputation. MDI and baseline PSS scores were missing for 0.2% of participants. PSS 
scores on the early pregnancy questionnaire were missing for 18.0% of participants. Use 
of psychotropic medications in pregnancy was missing for 16.0% of participants, and 
gestational age at delivery was missing for 23.7% of participants. Covariate missingness 
ranged from 0.0% (age) to 3.9% (income). All frequencies are reported from the first 
imputed dataset.   
 
Following imputation, we excluded women who reported a pregnancy loss (miscarriage, 
ectopic pregnancy, induced abortion) prior to 20 weeks’ gestation (n=691) or whose 
imputed gestational age at delivery was less than 20 weeks’ gestation (n=163-203), 
yielding imputed datasets ranging in size from 2,621 to 2,661 women. Those excluded 
had similar baseline MDI and PSS scores, and were as likely to report pre-pregnancy use 
of psychotropic medications as women included in the analytic cohort (Table 2.2).  
  
We used the Anderson-Gill data structure with one observation per week of gestation to 
account for varying lengths of gestation.37–39 Participants contributed gestational weeks to 
the analysis starting at 20 weeks until delivery (live birth or pregnancy loss). We used 
restricted mean survival time (RMST) models to calculate mean gestational age at 
delivery among women who initiated use of psychotropic medications during pregnancy, 
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those who used medications before and during pregnancy, those who used medications 
before but not during pregnancy, and those who never used medications (reference 
group). RMST models are used to estimate the mean survival time up to a pre-specified 
cut-point. We used a cut-point of 43 weeks’ gestation, after which delivery is rare. The 
RMST is equivalent to the area under a Kaplan-Meier curve. RMST models are 
advantageous because they provide intuitive estimates of average survival time and do 
not have any model assumptions.40,41 We also used Cox proportional hazards regression 
models to assess the association between psychotropic medication use and time to 
delivery. We used log-binomial regression models to evaluate the cumulative incidence 
of preterm delivery by use of psychotropic medications. 
  
To evaluate the extent to which these associations may have been confounded by 
indication, we repeated these analyses after stratifying the data by baseline MDI score, 
baseline PSS score, and early pregnancy PSS score. As few women reported using 
psychotropic medications during pregnancy, we combined the women who initiated 
psychotropic medication usage during pregnancy (n=51) )and those who used 
medications before and during pregnancy (n=154) into one group in these analyses.  
 
We adjusted all models for potential confounders selected based on a review of the 
literature and the use of a directed acyclic graph (Figure 2.1). The directed acyclic graphs 
for baseline MDI score, baseline PSS score, and early pregnancy PSS score were similar. 
All models were adjusted for age at enrollment (years), BMI (kg/m2), marital status 
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(married vs. not), employment status (currently employed full- or part-time vs. not), 
race/ethnicity (non-Hispanic white vs. not), annual household income (<$50,000, 
$50,000-$99,999, $100,000-$149,999, ≥$150,000), smoking (current vs. former/never), 
alcohol intake (drinks/week), history of preterm delivery (yes vs. no), history of infertility 
(yes, no, never tried to conceive), and history of clinically diagnosed depression and 
panic/anxiety disorder (yes vs. no). In analyses of psychotropic medication use stratified 
by MDI and PSS scores, we further adjusted for continuous MDI or PSS scores within 
each stratum. 
 
2.3 RESULTS 
Two hundred and five (7.8%) participants reported using psychotropic medications 
during pregnancy, with 75.0% of these women also reporting use of psychotropic 
medications before pregnancy. The majority of participants (88.3%) had baseline MDI 
scores <20 (no/low depressive symptoms), while 2.8% had scores ≥30 (severe depressive 
symptoms). About 45% of participants had baseline PSS scores below 15, and the 
proportion of women with baseline PSS scores ≥25 was 6.9%. The majority of 
participants (61.3%) had early pregnancy PSS scores that were within four points of their 
baseline scores, while 11.2% had early pregnancy scores that were >4 points higher and 
27.5% had scores that were <4 points lower than their baseline PSS scores.  
 
Women who used psychotropic medications during pregnancy were less likely to have an 
annual household income >$50,000 and to be employed full-time than women who did 
not use psychotropic medications during pregnancy (Table 2.3). These women also were 
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more likely to have had a prior preterm birth than women who did not use psychotropic 
medications during pregnancy. Participants with severe depressive symptoms were less 
likely to have at least a college education and an annual household income >$50,000 and 
more likely to report a diagnosis history of depression or anxiety/panic disorder, prior use 
of psychotropic medications, and a previous preterm delivery than participants with 
no/low/mild/moderate depressive symptoms. We observed similar associations with 
baseline PSS scores, although participants with scores of 20-24 also were more likely to 
report a diagnosis history of depression and anxiety/panic disorder and psychotropic 
medication use.  
 
Unadjusted analyses showed that women who used psychotropic medications during 
pregnancy delivered earlier than women who did not (Figure 2.2). After accounting for 
potential confounders, participants who used psychotropic medication during pregnancy 
(HR: 1.20; 95% CI: 1.00, 1.44) delivered slightly earlier relative to never users of 
psychotropic medications (Table 2.4). However, the differences in mean gestational ages 
at delivery among these groups were relatively small, and consistent with random 
variation. Participants who never used psychotropic medications delivered at a mean of 
38.1 weeks (95% CI: 37.5, 38.6), while those who used medications in pregnancy 
delivered at a mean of 37.2 weeks (95% CI: 36.4, 37.9). MDI and PSS scores were not 
appreciably associated with time to delivery (Table 2.4).  
 
Overall, 8.7% of participants had a preterm delivery. The cumulative incidence of 
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preterm delivery was similar among women who never used psychotropic medications 
(9.7%), those who used medications before but not during pregnancy (8.7%), and those 
who used medications during pregnancy (11.0%). The cumulative incidence of preterm 
delivery, however, was higher among participants who initiated use during pregnancy 
(15.3%). Participants who initiated use during pregnancy were more likely to have a 
preterm delivery than women who never used medications (RR: 1.66; 95% CI: 0.91, 
3.07). Although imprecisely estimated, the RR comparing women who used psychotropic 
medications before and during pregnancy with women who never used psychotropic 
medications was 1.26 (95% CI: 0.59, 2.27).  
 
Among women with MDI scores <25, those who used psychotropic medications during 
pregnancy delivered at a mean gestational age of 37.2 weeks (95% CI: 36.5, 38.0) while 
those who never used medications delivered slightly later at 38.1 weeks (95% CI: 37.5, 
38.7; Table 2.5). Among women with MDI scores ≥20, those who used psychotropic 
medications during pregnancy delivered at a mean gestational age of 36.3 weeks (95% 
CI: 33.4, 39.1) while those who never used medications delivered slightly later at 36.8 
weeks (95% CI: 34.2, 39.4; Table 2.5). 
 
We observed that women who used psychotropic medications during pregnancy delivered 
earlier than women who never used psychotropic medications, and that the association 
was relatively uniform across strata of baseline stress severity (Table 2.5). Differences in 
mean gestational age at delivery between women who used psychotropic medications 
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during pregnancy and those who never used medications, however, were small and 
consistent with random variation. Among women with baseline PSS scores <20 those 
who used psychotropic medications during pregnancy delivered at a mean of 37.2 weeks 
(95% CI: 36.3, 38.2) while those who never used medications delivered at a mean of 38.1 
weeks (95% CI: 37.5, 38.8). Among women with baseline PSS scores ≥20, those who 
used medications during pregnancy delivered at a mean of 36.8 weeks (95% CI: 35.4, 
38.2) and those who never used medications delivered at a mean of 37.8 weeks (95% CI: 
36.6, 38.9). 
 
Women who used psychotropic medications during pregnancy also delivered earlier than 
women who never used medications, across strata of early pregnancy stress (Table 2.5). 
As in the analyses stratified by baseline PSS, we observed small differences in mean 
gestational age at delivery between women who used psychotropic medications during 
pregnancy and those who never used medications that were consistent with random 
variation. Among women with early pregnancy PSS scores <20, those who used 
psychotropic medications during pregnancy delivered at a mean of 37.6 weeks (95% CI: 
36.8, 38.5) while those who never used medications delivered at a mean of 38.1 weeks 
(95% CI: 37.4, 38.7). Among women with early pregnancy PSS scores ≥20, those who 
used medications during pregnancy delivered at a mean of 35.9 weeks (95% CI: 34.3, 
37.5) while those who never used medications delivered at a mean of 37.9 weeks (95% 
CI: 36.8, 39.0). 
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2.4 DISCUSSION  
In this study of North American pregnancy planners, psychotropic medication use during 
pregnancy was associated with slightly earlier gestational ages at delivery. These 
differences in gestational age, however, were small and not clinically significant. Users 
of psychotropic medications during pregnancy tended to deliver one-half to one week 
earlier than women who did not use medications during pregnancy. We observed these 
associations among women with both high and low levels of preconception depressive 
symptoms and perceived stress (measured before and during pregnancy). In our study, 
depressive symptoms and perceived stress were not appreciably associated with 
gestational age to delivery.  
 
Our finding that psychotropic medication use during pregnancy is associated with slightly 
shorter gestations is consistent with previous results.15,42  Although we had limited study 
size to assess psychotropic medication use in relation to preterm delivery as a 
dichotomized variable, our results suggest that initiating use of psychotropic medications 
during pregnancy may increase the risk of preterm delivery. However, as women who 
used psychotropic medications both before and during pregnancy were as likely to deliver 
preterm as women who did not use medications, it is possible that the increased risk may 
be due to factors that caused the initiation.  
 
Previous studies of the associations between depression and stress in pregnancy and 
preterm delivery have shown positive associations.43–45 Although most of the studies 
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investigating stress and preterm delivery did not also assess the use of psychotropic 
medications, prior research has shown that women with untreated depression in 
pregnancy are more likely to deliver preterm than women without depression.45 In 
contrast, we found that depressive symptoms and perceived stress were not associated 
with time to delivery, regardless of symptom severity. The prevalence of preterm delivery 
in our cohort was also lower than is typical in the United States.46  It is possible that in a 
population of pregnancy planners such as ours, women may have healthier behaviors, 
more social support, and may be more adherent to prenatal care schedules and guidelines, 
which have been shown to buffer the association between depression and stress exposures 
and risk of preterm delivery.47–53  
 
By estimating time to delivery using RMST models we were able to provide more 
interpretable estimates of gestational age at delivery to complement our hazard ratio 
estimates from the Cox regression models. In our stratified analyses we found small 
differences in mean gestational age between women who used psychotropic medications 
during pregnancy and women who never used medications, despite moderately sized 
hazard ratios. This finding is not surprising as RMST models have been shown to yield 
more conservative results.41  
 
Misclassification of gestational age at delivery was possible. When available, we used the 
obstetric estimate of gestational age from birth registries, which is determined using early 
pregnancy ultrasounds in addition to last menstrual period.31  Although we also relied on 
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self-reported estimates of gestational age at delivery, these data were collected within six 
months of delivery, reducing the magnitude of reporting error. Despite this potential 
reporting error, in our cohort, we have found good agreement between self-reported 
gestational age at delivery and the obstetric estimate of gestational age at delivery 
(manuscript in preparation).  
 
We think it is unlikely that our results are prone to appreciable selection bias. To reduce 
the possibility of bias due to loss to follow-up, we imputed gestational age for all 
participants who reported a conception but provided no further follow-up information. 
Although we excluded women with pregnancy losses <20 weeks, they were similar to 
women included in this analysis with respect to baseline MDI and PSS scores, and 
history of psychotropic medication use. Recruitment of volunteers should not introduce 
bias, unless the association between the study factors differed between those who 
volunteered and those who did not. We do not believe that the association between 
psychotropic medication use and gestational age at delivery would differ between 
Internet-recruited volunteers and non-participants. Furthermore, studies have shown that 
even when participants differ in characteristics such as age, parity, or smoking at time of 
cohort entry, this self-selection does not bias the measured associations.54–56 Additionally, 
by using internet-based recruitment methods, we were able to recruit participants from all 
50 states in the U.S. and all 10 Canadian provinces, thereby increasing the 
generalizability of our findings.57 
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Although we were able to assess changes in perceived stress from baseline through early 
pregnancy, we collected data on depressive symptoms at baseline only (i.e., before 
pregnancy). Therefore, we were not able to evaluate the associations of these conditions 
in pregnancy with time to delivery. However, pre-pregnancy depression is a strong 
predictor of prenatal depression; therefore, any misclassification is likely small.58–61 The 
associations between perceived stress and time to delivery were similar, whether 
perceived stress was measured at baseline or during early pregnancy, further indicating 
that this is not an important source of bias. The relatively small size of our sample 
precluded our ability to assess associations by preterm birth subtypes (medically-
indicated vs. spontaneous). Thus, if there are important differences in the effect of 
psychotropic medication use on preterm delivery by preterm birth subtype, our 
associations would have been attenuated.62,63 Immortal person-time bias may have 
attenuated our effects if women who delivered early did not have the opportunity to be 
exposed to psychotropic medications. However, almost all users of psychotropic 
medications during pregnancy used medications in the first and second trimesters (see 
Table 2.1).   
 
2.5 CONCLUSION 
Among pregnancy planners, women who use psychotropic medications during pregnancy 
may deliver slightly earlier than women who do not, though these differences may not be 
clinically significant. We observed these associations among women with both high and 
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low levels of depressive symptoms and perceived stress, suggesting little confounding by 
indication.   
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2.6 TABLES 
Table 2.1: Psychotropic medication use stratified by MDI and PSS scores 
 Overall Baseline 
MDI Score 
Baseline 
PSS score 
Early pregnancy 
PSS score 
  <25 ≥25 <20 ≥20 <20 ≥20 
Number of women 2,641 2,492 149 2,015 626 2,148 493 
Psychotropic medication use        
None 1,885 (71.4) 1,817 (72.9) 68 (45.6) 1,556 (77.2) 329 (52.6) 1,601 (74.5) 284 (57/6) 
Before but not during pregnancy 551 (20.9) 498 (20.0) 53 (35.6) 343 (17.0) 208 (33.2) 407 (19.0) 144 (29.3) 
Before and during pregnancy 154 (5.8) 131 (5.3) 23 (15.4) 78 (3.9) 76 (12.1) 101 (4.7) 53 (10.8) 
Initiated during pregnancy 51 (1.9) 46 (1.9) 5 (3.4) 38 (1.9) 13 (2.1) 39 (1.8) 12 (2.4) 
Use by trimester among women who 
used psychotropic medications during 
pregnancy a 
       
First trimester only 10 (4.9) 10 (5.7) 0 (0.0) 8 (6.9) 2 (2.3) 6 (4.3) 4 (6.2) 
Second trimester only 7 (3.4) 5 (2.8) 2 (7.1) 5 (4.3) 2 (2.3) 5 (3.6) 2 (3.1) 
Third trimester only 8 (3.9) 8 (4.5) 0 (0.0) 5 (4.3) 3 (3.4) 7 (5.0) 1 (1.5) 
First and second trimesters 8 (3.9) 7 (4.0) 1 (3.6) 5 (4.3) 3 (3.4) 7 (5.0) 1 (1.5) 
First and third trimesters 5 (2.4) 4 (2.3) 1 (3.6) 3 (2.6) 2 (2.3) 3 (2.1) 2 (3.1) 
Second and third trimesters 30 (14.6) 25 (14.1) 5 (17.9) 18 (15.5) 12 (13.5) 21 (15.0) 9 (13.9) 
Frist, second, and third trimesters 137 (66.8) 118 (66.7) 19 (67.9) 72 (62.1) 65 (73.0) 91 (65.0) 46 (70.8) 
     a Includes 154 (75%) women who were using before and during pregnancy, and 51 (25%) women who initiated use during pregnancy. 
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Table 2.2: Baseline MDI score, PSS score, and history of psychotropic medication use among women included and excluded from 
analytic cohort 
 Included in analytic cohort Excluded for pregnancy loss <20 weeksa 
Number of women 2,641 874 
Baseline MDI score   
Median (IQR) 7.0 (4.0, 13.0) 8.0 (4.0, 13.0) 
None/low [<20] 2,333 (88.3) 766 (87.6) 
Mild [20-24] 159 (6.0) 40 (4.6) 
Moderate [25-29] 73 (2.8) 31 (3.6) 
Severe [≥30] 76 (2.9) 37 (4.3) 
Baseline PSS score   
Median (IQR) 15.0 (12.0, 19.0) 15.0 (12.0, 19.0) 
<15 1,181 (44.7) 391 (44.7) 
15-19 834 (31.6) 275 (31.5) 
20-24 446 (16.9) 143 (16.4) 
≥25 180 (6.8) 65 (7.4) 
History of psychotropic medication use 705 (26.7) 260 (29.8) 
a Includes 691 (79%) women who reported a pregnancy loss and 183 (21%) women who had an imputed gestational age at delivery <20 weeks. 
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Table 2.3: Baseline characteristics of 2,641 pregnant women enrolled in PRESTO by psychotropic medication use, MDI score, and 
PSS score (2013-2018) a 
 Psychotropic medication use Baseline MDI score Baseline PSS score 
 None 
Before 
but not 
during 
pregnancy 
Before 
and during 
pregnancy 
Initiated 
during 
pregnancy 
<20 20-24 25-29 ≥30 <15 15-19 20-24 ≥25 
Number of women (%) 1,885 (71.4) 
551 
(20.9) 
154 
(5.8) 
51 
(1.9) 
2,333 
(88.3) 
159 
(6.0) 
73 
(2.8) 
76 
(2.9) 
1,181 
(44.7) 
834 
(31.6) 
446 
(16.9) 
180 
(6.6) 
Age, years (mean) 29.7 29.9 30.3 30.2 29.9 29.3 29.1 29.0 30.0 29.6 29.6 29.6 
Body mass index, kg/m2 
(mean) 25.8 26.8 27.1 27.7 25.8 27.8 28.6 31.2 25.4 26.1 27.1 28.6 
Non-Hispanic white (%) 84.3 88.8 88.4 81.5 86.0 82.5 87.0 69.3 86.9 85.1 84.2 79.5 
Less than college 
education (%) 17.7 24.4 17.8 25.9 17.2 31.9 27.3 49.3 14.6 20.0 24.1 35.1 
Household income 
≤$50,000 USD (%) 14.4 17.0 19.2 24.1 13.4 24.8 23.3 50.7 10.5 16.8 19.7 30.8 
Married (%) 96.7 93.7 97.3 92.6 96.1 93.8 94.8 96.0 97.4 94.6 95.6 94.1 
Employed full-time (%) 88.6 84.4 84.3 79.6 88.6 76.3 84.4 70.7 89.8 87.2 84.5 77.3 
Current smoker (%) 7.4 10.4 11.0 22.2 7.7 10.6 13.0 26.7 7.0 9.2 8.8 14.6 
History of depression or 
anxiety (%) 6.4 100.0 100.0 5.5 28.5 47.5 53.3 69.3 20.7 32.2 49.9 55.7 
History of psychotropic 
medication use (%) - - - - 24.3 36.9 49.4 58.7 17.8 25.9 43.9 49.7 
Alcohol intake, 
drinks/week (mean) 3.3 3.6 4.4 4.3 3.4 3.9 4.1 4.5 3.5 3.3 3.4 4.1 
Caffeine intake, mg/day 
(mean) 120.3 137.2 149.6 131.1 123.8 142.9 126.0 151.0 120.8 127.0 131.3 138.8 
Physical activity, MET-
hours/week (mean) 35.8 34.0 35.0 32.6 36.1 32.1 29.0 25.5 37.9 34.9 32.8 26.4 
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Gravidity (mean) 0.8 0.9 1.0 1.3 0.8 1.2 1.0 1.5 0.8 0.8 1.0 1.2 
Parous (%) 30.0 29.3 28.8 39.9 29.0 39.3 27.3 42.7 29.8 27.7 32.0 36.2 
Participant herself born 
preterm (%) 10.0 7.9 11.6 3.7 8.7 15.0 7.8 13.3 8.6 7.8 12.1 13.0 
History of preterm birth 
b (%) 11.3 13.1 18.2 25.0 12.1 11.1 4.4 27.3 11.9 12.4 10.0 20.0 
History of miscarriage c 
(%) 45.0 47.1 48.1 55.2 45.5 46.3 56.8 47.1 42.4 46.2 50.5 53.6 
History of infertility d 
(%) 11.3 10.8 14.0 25.0 10.2 20.7 15.7 25.4 8.2 12.9 14.7 19.1 
MDI=Major Depressive Inventory, PSS=Perceived Stress Scale, USD=United States Dollar, MET=metabolic equivalent of task. 
a Characteristics are standardized to age distribution of cohort at baseline. 
b Restricted to 807 participants who reported a prior delivery. 
c Restricted to 1,274 participants who reported a prior pregnancy. 
d Restricted to 1,626 participants who tried to conceive 
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Table 2.4: Psychotropic medication use and MDI and PSS scores in relation to time to delivery  
   Time to delivery 
 n 
Adjusted mean 
gestational age at 
delivery (95% CI) 
Crude 
hazard ratio 
(95% CI) 
Adjusted a 
hazard ratio 
(95% CI) 
Fully adjusted b 
hazard ratio  
(95% CI) 
Psychotropic medication use      
Never 1,885 38.1 (37.5, 38.6) REF REF - 
Before but not during pregnancy 551 37.5 (36.8, 38.1) 1.01 (0.92, 1.11) 1.05 (0.92, 1.21) - 
During pregnancy 205 37.2 (36.4, 37.9) 1.14 (0.99, 1.31) 1.20 (1.00, 1.44) - 
Before and during pregnancy 154 37.4 (36.5, 38.2) 1.12 (0.95, 1.31) 1.20 (0.92, 1.51) - 
Initiated during pregnancy 51 36.8 (35.4, 38.2) 1.23 (0.94, 1.61) 1.20 (0.90, 1.60) - 
Baseline MDI score      
None/low [<20] 2,333 37.7 (37.2, 38.2) REF REF REF 
Mild [20-24] 159 37.8 (37.0, 38.5) 1.07 (0.91, 1.26) 1.05 (0.89, 1.23) 1.05 (0.89, 1.24) 
Moderate [25-29] 73 38.1 (37.3, 39.0) 0.98 (0.78, 1.23) 0.97 (0.77, 1.22) 0.96 (0.76, 1.21) 
Severe [≥30] 76 37.6 (36.5, 38.7) 1.04 (0.83, 1.32) 0.97 (0.76, 1.23) 0.97 (0.76, 1.23) 
MDI score (per 10-unit increase) - - 1.02 (0.97, 1.07) 1.05 (0.94, 1.17) 1.04 (0.94, 1.15) 
Baseline PSS score       
<15 1,181 37.9 (37.4, 38.4) REF REF REF 
15-19 834 37.9 (37.4, 38.3) 1.02 (0.94, 1.12) 1.02 (0.93, 1.12) 1.02 (0.94, 1.12) 
20-24 446 37.6 (37.1, 38.2) 1.06 (0.95, 1.18) 1.04 (0.93, 1.17) 1.04 (0.93, 1.17) 
≥25 180 37.6 (36.9, 38.3) 1.08 (0.92, 1.26) 1.04 (0.89, 1.22) 1.04 (0.88, 1.22) 
PSS score per 10-unit increase - - 1.05 (0.98, 1.12) 1.05 (0.94, 1.17) 1.04 (0.94, 1.17) 
Early pregnancy PSS score       
<15 1,500 37.8 (37.4, 38.3) REF REF REF 
15-19 648 37.9 (37.4, 38.4) 0.99 (0.91, 1.09) 1.02 (0.93, 1.12) 1.02 (0.93, 1.12) 
20-24 348 37.9 (37.3, 38.5) 0.97 (0.86, 1.09) 1.04 (0.93, 1.17) 1.04 (0.93, 1.17) 
≥25 145 37.5 (36.7, 38.2) 1.10 (0.93, 1.30) 1.04 (0.89, 1.22) 1.04 (0.89, 1.22) 
PSS score per 10-unit increase - - 1.02 (0.96, 1.08) 1.05 (0.94, 1.17) 1.05 (0.93, 1.18) 
a Adjusted for age at enrollment, BMI, race, marital status, employment status, income, smoking, alcohol intake, history of preterm delivery, 
history of infertility, history of clinically diagnosed depression and/or anxiety/panic disorder. 
b Further adjusted for psychotropic medication before pregnancy. 
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Table 2.5: Psychotropic medication use in relation to time to delivery, stratified by MDI and PSS scores 
  Time to delivery 
 n Adjusted mean gestational age at delivery (95% CI) 
Crude hazard ratio 
(95% CI) 
Adjusted a hazard ratio 
(95% CI) 
Psychotropic medication use     
None 1,885 38.1 (37.5, 38.6) REF REF 
Before but not during pregnancy 551 37.5 (36.8, 38.1) 1.02 (0.93, 1.12) 1.14 (0.95, 1.36) 
During pregnancy 205 37.2 (36.4, 37.9) 1.10 (0.95, 1.28) 1.18 (0.98, 1.43) 
Baseline MDI score <25     
Psychotropic medication use     
None 1,817 38.1 (37.5, 38.7) REF REF 
Before but not during pregnancy 498 37.4 (36.7, 38.0) 1.02 (0.92, 1.12) 1.15 (0.95, 1.38) 
During pregnancy 177 37.2 (36.5, 38.0) 1.10 (0.94, 1.28) 1.18 (0.97, 1.44) 
Baseline MDI score ≥25     
Psychotropic medication use     
None 68 36.8 (34.2, 39.4) REF REF 
Before but not during pregnancy 53 37.7 (35.2, 40.1) 1.08 (0.75, 1.54) 1.19 (0.56, 2.53) 
During pregnancy 28 36.3 (33.4, 39.1) 1.24 (0.78, 1.96) 1.46 (0.68, 3.16) 
Baseline pregnancy PSS score <20     
Psychotropic medication use     
None 1,556 38.1 (37.5, 38.8) REF REF 
Before but not during pregnancy 343 37.8 (37.0, 38.5) 0.97 (0.87, 1.09) 1.07 (0.87, 1.33) 
During pregnancy 116 37.2 (36.3, 38.2) 1.14 (0.94, 1.37) 1.20 (0.96, 1.51) 
Baseline pregnancy PSS score ≥20     
Psychotropic medication use     
None 329 37.8 (36.6, 38.9) REF REF 
Before but not during pregnancy 208 36.8 (35.6, 37.9) 1.09 (0.92, 1.30) 1.25 (0.90, 1.75) 
During pregnancy 89 36.8 (35.4, 38.2) 1.06 (0.83, 1.34) 1.18 (0.84, 1.66) 
Early pregnancy PSS score <20     
Psychotropic medication use     
None 1,601 38.1 (37.4, 38.7) REF REF 
Before but not during pregnancy 407 37.6 (36.9, 38.3) 1.02 (0.92, 1.14) 1.15 (0.93, 1.42) 
During pregnancy 140 37.6 (36.8, 38.5) 1.06 (0.89, 1.27) 1.12 (0.90, 1.40) 
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Early pregnancy PSS score ≥20     
Psychotropic medication use     
None 284 37.9 (36.8, 39.0) REF REF 
Before but not during pregnancy 144 36.8 (35.6, 38.1) 1.01 (0.83, 1.24) 1.16 (0.82, 1.64) 
During pregnancy 65 35.9 (34.3, 37.5) 1.21 (0.92, 1.58) 1.39 (0.96, 2.00) 
n=number of women. 
a Adjusted for age at enrollment, BMI, race, marital status, employment status, income, smoking, alcohol intake, 
history of preterm delivery, history of infertility, history of clinically diagnosed depression and/or anxiety/panic 
disorder, and continuous MDI or PSS score 
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2.7 FIGURES 
Figure 2.1: Directed acyclic graph 
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Figure 2.2: Incidence of delivery per 1,000 fetus weeks by psychotropic medication 
use during pregnancy; gestational age truncated at 42 weeks 
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3.0 ADVERSE PSYCHOSOCIAL FACTORS IN PREGNANCY AND 
GESTATIONAL AGE AT DELIVERY  
 
3.1 BACKGROUND 
Annually, approximately 10% of infants in the U.S. are delivered preterm (<37 weeks’ 
gestation).1 Preterm delivery is associated with increased risks of neonatal mortality and 
morbidity, as well as neurodevelopmental disabilities in childhood and adulthood.2  
 
Mental health symptoms (depression and anxiety), stress, and low psychosocial resources 
(social support and resilience) have been associated with preterm delivery in previous 
studies.3–8 Many of these psychosocial factors tend to co-occur in women and studies 
have shown that women who experience more than one of these factors are more likely to 
deliver preterm than women who experience only one factor.9,10 Thus, understanding 
what combinations of adverse psychosocial factors women commonly experience during 
pregnancy may allow for better prediction of preterm delivery. Additionally, identifying 
combinations of adverse psychosocial factors may help clinicians more effectively target 
treatments. 
 
In this study, we conducted a latent class analysis to identify groups of pregnant women 
with similar combinations of adverse psychosocial factors as measured by widely-used 
psychometric instruments. In addition, we investigated how gestational age at delivery 
and preterm delivery differed among the latent classes. 
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3.2 METHODS 
 
3.2.1 Study population 
Spontaneous Prematurity and Epigenetics of the Cervix (SPEC) is a prospective cohort 
study of pregnant women. Women who are at least 18 years old and are seeking prenatal 
care at Beth Israel Deaconess Medical Center in Boston, Massachusetts are eligible to 
participate. Women can enroll in SPEC at any point during pregnancy (median 
gestational age at enrollment: 18.0 weeks; range: 5.0–34.0 weeks), and those who 
conceive more than once can reenroll. The majority of participants complete 
demographic and psychosocial questionnaires in-person at enrollment (54.4%) or via 
email 1–2 weeks after enrollment (14.0%).   
SPEC participants with singleton gestations, who enrolled in the study after August 24, 
2014 (when the resilience instrument was added), and who delivered by January 20, 2019 
were eligible for inclusion in this analysis (n=1,011). We excluded participants who 
completed their psychometric questionnaires in the third trimester (n=111) or after 
delivery (n=55), or who reported a pregnancy loss (miscarriage, ectopic pregnancy, 
induced abortion) prior to 20 weeks’ gestation (n=141). Thirteen (1.8%) participants 
contributed more than one pregnancy to the analysis. Our final analytic sample included 
691 women with 704 pregnancies.  
3.2.2 Psychometric measures 
Depression 
Antenatal depressive symptoms were measured using the 10-item Edinburgh Postnatal 
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Depression Scale (EPDS), which has been validated for use among pregnant women.11,12 
Scores range from 0–30, with higher scores indicating more depressive symptoms. 
Participants reported the frequency with which they experienced depressive symptoms 
within the previous seven days.  
 
General anxiety 
General anxiety was measured using the 10-item version of the Trait Anxiety Scale, 
which is part of the State-Trait Anxiety Inventory.13 Participants rated how often they 
experienced symptoms of anxiety on a scale from one (“almost never”) to four (“almost 
always”). Scores range from 10–40, with higher scores indicating more anxiety 
symptoms. Although the 10-item version has not been validated for use among pregnant 
women, the 20-item version has.14  
 
Pregnancy-related anxiety 
Participants completed the 7-item Pregnancy-Related Anxiety Scale 15 Participants were 
asked to rate their level of concern from one (“not at all”) to four (“very much”). Scores 
range from 4–28, with higher scores indicating higher anxiety. This instrument has not 
been validated, but has been used in similar populations.16,17  
 
Perceived stress 
Perceived stress was ascertained using Cohen’s 4-item Perceived Stress Scale, which has 
been used in similar populations.14,18–20 Participants reported the frequency of stressful 
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experiences within the past month on a scale from zero (never) through five (very often). 
Overall scores range from 0–20, with higher scores indicating greater perceived stress.  
 
Stressful events 
Participants completed the Crisis in Family Systems-Revised based on their experience 
within the last six months.21 This scale asks about stressful events within 11-domains, 
including: financial, relationship, safety at home, and medical issues.21 If a participant 
stated that she experienced at least one of the events within a given domain and that it 
had a negative impact on her, she received one point towards her total score. Scores range 
from 0–11, with 11 indicating that a participant has recently experienced many stressful 
events. This scale has not been validated among pregnant women, but has been used in 
other pregnancy studies.22,23  
 
Social support 
Participants completed two sets of five Likert-scale questions regarding their social 
support. The first set was specific to support from their partner, and are a subset of the 
eight questions developed by Turner et al. to evaluate partner support among pregnant 
teenagers.24 The second set are a subset of the Provisions of Social Relation Scale and 
were used to capture support from family and friends.24 Although these questions are not 
specific to pregnancy, both scales were developed and validated for use among pregnant 
women.24 Scores range from 0–15 for each scale, with higher scores indicating higher 
support. Consistent with prior research, we classified women who reported not having a 
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partner as having low partner support.25  
 
Resilience 
Resilience was measured using the 25-item Connor-Davidson Resilience Scale.26 
Although this scale has not been validated for use among pregnant women, it has been 
used in other studies of pregnancy.27,28 Participants were asked to respond to each item 
based on their experience within the past month. Scores range from 0-100, with higher 
scores indicating higher resilience.  
 
3.2.3 Gestational age at delivery 
Gestational age at delivery was abstracted from medical records for all participants who 
delivered at BIDMC (92.3%). We telephoned participants who did not deliver at BIDMC 
to obtain delivery information, including gestational age. We attempted to contact 
participants three times. After the third attempt we considered unreachable participants as 
lost to follow-up.  
 
3.2.4 Statistical analyses 
We conducted a latent class analysis to identify combinations of adverse psychosocial 
factors experienced by participants during pregnancy. Latent class analysis is an analytic 
technique used to identify homogenous groups (classes) of individuals. Although class 
membership is unknown, it can be inferred from response patterns to a set of categorical 
variables.29–31  It resembles cluster analysis in that the goal is to categorize individuals 
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into groups using statistical criteria determined from fitting data to models with different 
numbers of classes. As with cluster analysis, the number of classes is not estimated a 
priori, but is instead determined based on model-fit. Unlike cluster models, however, 
membership in a latent class is determined based on the probability of group 
membership—similar to a predicted probability of the outcome estimated from a set of 
variables in a regression model—which is calculated from the modeled variables.  
 
We used multiple imputation to impute missing data from the psychometric measures, as 
well  as gestational age at delivery for participants lost to follow-up.32 We generated five 
imputation data sets using a Markov chain Monte Carlo method.33 We imputed missing 
responses to individual questions and then scored each psychometric measure, rather than 
imputing the overall score. The proportion of missingness for questions on the 
psychometric measures ranged from 18.1% to 26.4%. Gestational age at delivery was 
missing for 1.3% of participants.  
 
After we imputed we created dichotomous variables for scores on each of the 
psychometric measures to use in our latent class analysis. Although dichotomization of 
variables has been shown to have a number of problems, we chose to create binary levels 
in order to be able to identify groups of women with the highest (or lowest in the case of 
psychosocial resources) levels of our factors of interest.34 We used the established cut-
point of 13 on the EPDS to classify participants as having probable depression (vs. non-
probable depression).35–37 To our knowledge there are no validated cut-points for any of 
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the other psychometric measures that we used, so we created cut-points based on the 
distribution of scores in the cohort.  We considered participants with scores ³ the 90th 
percentile on the general anxiety (23 points), pregnancy-related anxiety (21 points), 
perceived stress (10 points), and recent experience of stressful life events (5 events) as 
having high anxiety or stress (vs. moderate/low). We classified participants with scores ≤ 
10th percentile on the resilience (57 points) and both social support scales (9 points for 
friend/family and 10 points for partner) as having low psychosocial resources (vs. 
moderate/high). We choose these cut-points because we felt that the scores ³ 90th and ≤ 
10th percentiles were most indicative of adverse symptomology, which was overall fairly 
low in the cohort (Table 3.1).  
 
For each of the five imputed datasets, we fit four models with between two and five 
classes to our data, and then averaged the model fit statistics and conditional probabilities 
across the five imputed datasets. We assessed model fit using the Akaike information 
criterion (AIC), the Bayesian information criterion (BIC), the sample-size adjusted BIC, 
the Lo-Mendell-Rubin adjusted likelihood ratio test (LMR-A), and entropy values.38–40 
For the AIC, BIC, and sample-size adjusted BIC, lower values indicate better fit, while 
for the LMR-A, a statistically significant result indicates that the model fits the data 
better than a more parsimonious model with one fewer class (e.g. three classes fits the 
data better than two classes). Entropy values range from zero to one, with values closer to 
one indicating better separation between the classes.29  We used the conditional 
probabilities of class membership to characterize the classes. We did not consider how 
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well models with different numbers of classes predicted preterm delivery in our decision, 
as our primary objective was to identify patterns of adverse psychosocial factors.  
 
After identifying the model with the best fit, we used each participant’s posterior 
probability of class membership to assign them to their most likely class. The posterior 
probability of membership in a particular latent class can be expressed as: 
 !(# = %|' = () 	= 	!(# = %)!(' = (|# = %)!(' = () 	,	
 
where C represents the latent class variable with c=1-K latent classes and Y represents an 
individual’s vector of responses to a set of observed variables (y). 
 
We used linear regression to compare mean gestational ages at delivery among the latent 
classes, using the class with few adverse psychosocial factors as the reference group. We 
used log-binomial regression to compare the cumulative incidence of preterm delivery 
among the classes, again using the class with few factors as the reference group.  We also 
compared mean gestational age at delivery and incidence of preterm delivery by each of 
the individual adverse psychosocial factors, in order to evaluate how each factor 
predicted these outcomes compared to the combination of factors identified in the latent 
class analysis.  
 
3.2.6 Sensitivity analyses 
Because we used data-driven cut-points to create binary variables for all of the 
psychometric measures except the EPDS, we repeated the latent class analysis described 
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above using lower thresholds for adverse levels of anxiety, stress, and low psychosocial 
resources to evaluate the effect of our chosen cut-points. For this sensitivity analysis we 
considered scores ³ the 75th percentile on the general anxiety (20 points), pregnancy-
related anxiety (16 points), perceived stress (9 points), and recent experience of stressful 
life events (2 events) measures as having high anxiety or stress (vs. moderate/low). We 
classified participants with scores ≤ the 25th percentile on the resilience (66 points) and 
both social support scales (11 points for friend/family and 12 points for partner) as having 
low psychosocial resources (vs. moderate/high). We used the same cut-point of 13 for the 
EPDS to classify participants as having probable depression (vs. non-probable 
depression). 
 
Although severity of adverse psychosocial factors may vary throughout pregnancy, we 
measured these factors at one time point only. In our cohort, the median gestational age at 
which surveys were completed was 19.0 weeks (range: 4.0-27.0) with the majority of 
participants (65.9%) completing surveys during the first half of pregnancy (<20 weeks’ 
gestation). To evaluate whether the combinations of adverse psychosocial factors differed 
depending on when in pregnancy participants completed the psychometric measures, we 
repeated the latent class analysis among participants who completed the psychometric 
measures before 20 weeks’ gestation and compared these results to a latent class analysis 
conducted among participants who completed the psychometric measures after 20 weeks’ 
gestation. 
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This study was approved by the institutional review board at BIDMC. 
 
3.3 RESULTS 
3.3.1 Sample description 
The median gestational age at enrollment among our analytic sample was 18.0 weeks 
(IQR: 13.0-19.0); 183 (27.2%) women enrolled during the first trimester (<14 weeks). 
The median age among participants was 33.2 years (IQR: 30.3-36.3). Most participants 
were non-Hispanic white (57.1%), married or living with their partner (88.8%), and 
employed full-time (65.9%). Almost a third of participants reported that prior to their 
current pregnancy they had experienced symptoms of depression or anxiety (31.7%), 
received a clinical diagnosis of depression or anxiety (28.3%), or taken medications to 
treat depression or anxiety (29.5%; Table 3.2).  
 
3.3.2 Characterization of latent classes 
Results from the latent class analysis indicated that a two- or three-class model fit the 
data best. The two-class model had higher entropy than the three-class model (0.82 vs. 
0.73), while the AIC, BIC, and sample-size adjusted BIC were lower for the three-class 
model (Table 3.3). When we explored the conditional probabilities for each adverse 
psychosocial factor given latent class membership we observed clearer separation of the 
conditional probabilities among the classes for the three-class model (Tables 3.4 and 3.5). 
Based on the conditional probabilities and the model fit statistics, we determined that the 
three-class model fit the data best. 
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The largest class was class 1 (76.6% of cohort), followed by class 2 (20.3%), and class 3 
(3.1%). Participants in class 1  were unlikely to have probable depression (0.2%), high 
general anxiety (0.3%), high pregnancy-related anxiety (6.2%), and recent experience of 
five or more stressful life events (5.0%). They also were unlikely to have low 
psychosocial resources (2.0% - 4.1%). Participants in class 2 were somewhat more likely 
to have mental health symptoms—most notably high general anxiety (39.2%)—and low 
psychosocial resources (20.5% - 25.2%). Participants in class 3 were very likely to have 
probable depression (91.7%), high general anxiety (97.1%), high perceived stress 
(69.3%), and low resilience (72.1%). While only half of participants in this class were 
likely to have high pregnancy-related anxiety (51.7%), low friend/family support 
(55.3%), and low partner support (59.0%), the conditional probabilities of having these 
factors were much higher in this class as compared with participants in the other classes 
(Table 3.4).  
Participants in all three latent classes were similar with respect to age and history of 
preterm delivery (Table 3.6). Participants with some (79.8%) and many (55.6%) adverse 
psychosocial factors were less likely to report being married or living with their partner 
than participants with few adverse factors (92.7%). They were also more likely to report 
having a high-school education or less than women with few factors. Almost all (88.9%) 
of participants with many adverse factors reported experiencing symptoms of depression 
or anxiety prior to their current pregnancy, while the same was true for 50.9% of women 
with some adverse factors, and 23.7% of women with few factors. Women with many 
adverse factors were more likely to be black or Hispanic and have annual household 
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incomes less than <$25,000 than women with some or few factors. 
3.3.3 Adverse psychosocial factors in association with gestational age at delivery and 
preterm delivery 
The mean gestational age of delivery in the cohort was 39.0 weeks (SD: 2.0). The 
average gestational age at delivery was lower among participants with some adverse 
psychosocial factors (mean difference: -0.17; 95% CI: -0.76, 0.43) and many adverse 
factors (mean difference: -0.63; 95% CI: -3.67, 2.43), compared to those with few factors 
(Table 3.7). 
 
Overall 8.2% of participants delivered preterm; the incidence was 7.4% among women 
with few factors, 10.9% among those with some factors, and 9.1% among those with 
many factors. Participants with both some (RR: 1.50; 95% CI: 0.86, 2.62) and many 
adverse psychosocial factors (RR: 1.29; 95% CI: 0.36, 5.00) were more likely to deliver 
preterm than participants with few factors.  
 
Results from the models assessing mean gestational age at delivery and incidence of 
preterm delivery by each of the individual adverse factors were generally consistent with 
results from the models using the latent classes, with a few notable exceptions. When 
assessed individually, the RR for the association of high general anxiety with preterm 
delivery was 0.86 (95% CI: 0.40, 1.88). The RR for the association between high 
perceived stress and preterm delivery was 0.86 (95% CI: 0.45, 1.62). In contrast, the 
associations between depression and gestational age at delivery and preterm delivery 
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were stronger when depression was modeled independently.  
 
3.3.4 Sensitivity analyses 
When we used lower thresholds for adverse levels of anxiety, stress, and low 
psychosocial resources, we found that a four-class model fit the data best (Table 3.8). 
Class 4 was similar to class 3 from our primary analysis in that women were likely to 
have many adverse psychosocial factors, with high general anxiety being the most 
prevalent (95.6%). Women in each of the other classes were likely to experience at least 
one adverse factor, though the most prevalent factor varied among the classes (Table 3.9). 
Women in class 1 were most likely to have high perceived stress (44.4%), women in 
class 2 were most likely to have low social support (72.0% partner and 59.5% 
friend/family), and women in class 3 were most likely to have high general anxiety 
(70.4%) and low resilience (100.0%).  
 
Results from the latent class analysis among participants who completed the 
psychometric measures during the first half of pregnancy (<20 weeks’ gestation) were 
similar to those from the latent class analysis among participants in the second half of 
pregnancy. While the model fit statistics among both groups indicated that the two-class 
models fit the data somewhat better than the three-class models (Table 3.10), we again 
observed clearer separation between the conditional probabilities in the three-class 
models. The three classes we identified in both groups were similar to those identified 
from the latent class analysis among the full cohort (Table 3.11).   
  
53 
 
3.4 DISCUSSION 
In this study, we identified three common clusters of adverse psychosocial factors among 
women in pregnancy. Participants with few psychosocial factors were very unlikely to 
have depressive symptoms, high anxiety, and low psychosocial resources, though nearly 
20% reported high perceived stress. Participants with some psychosocial factors were 
more likely to have mental health symptoms, stress, and low resources, with high general 
anxiety being the most prevalent factor. Participants who experienced many adverse 
factors were most likely to have depressive symptoms and high anxiety, though more 
than half also reported high stress and low resources. Although the associations were 
imprecisely estimated, we also found that participants with some or many adverse 
psychosocial factors may have shorter gestations and may be more likely to deliver 
preterm than participants with few factors. 
The patterns of adverse psychosocial factors observed among the latent classes are 
generally consistent with other studies of psychosocial factors and pregnancy outcomes 
that have utilized latent variable analyses. In particular, our study supports the finding 
that women who experience depressive symptoms are also very likely to experience 
anxiety and stress.28,42 This suggests that if a woman is diagnosed with one of these 
conditions, it may be important to assess for comorbidities to inform the best intervention 
strategy.  
The American College of Obstetricians and Gynecologists recommends that women be 
screened once during pregnancy for depression and anxiety.43 Screening for multiple 
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adverse factors, however, may provide valuable information to help providers tailor 
treatment, especially for women who experience multiple factors. For example, women 
with many adverse factors may need more involved treatments and social support 
services to treat their mental health symptoms. As women with many adverse factors are 
more likely to be low-income and racial/ethnic minorities, clinicians may be able to best 
serve these women by recommending community-based interventions that do not require 
frequent trips to a provider. This may help overcome some of the challenges that prevent 
low income and minority women from receiving adequate treatment for mental health 
symptoms in pregnancy including lack of money, childcare, and stigma.44 
More than half of study participants with many adverse psychosocial factors had low 
social support. As these participants also were likely to have mental health symptoms and 
stress, a multifaceted treatment strategy that addresses mental health symptoms and also 
increases social support may be a more effective treatment strategy than addressing each 
issue in isolation. For example, these women may benefit from group prenatal care or in-
home counseling and assistance as these types of interventions can increase social 
support while addressing mental health symptoms and stress.45,46 
A notable limitation of this study was the homogeneity of our sample, as our cohort was 
comprised predominantly of white women who had at least a college education, were 
married, had an annual household income of $75,000 or higher, and had few adverse 
psychosocial factors. The homogeneity of the study population may limit the 
generalizability of our findings. Our ability to estimate the correct number of classes also 
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may have been limited by our sample size. If the analysis were repeated among a larger, 
more diverse population, we may have observed more latent classes with different 
combinations of adverse psychosocial factors. Additionally, we did not collect data on 
whether participants were actively receiving treatment for mental health symptoms or 
stress, or any additional support services. We may have identified different latent classes 
of women had these data been available for inclusion in our analysis.   
Our analysis is limited by our dichotomization of continuous measures. By dichotomizing 
each psychometric measure, we may have lost potentially meaningful information about 
the spectrum of symptom severity experienced by women in our cohort. This may be 
especially true for the psychometric measures that do not have validated cut-points. 
While our decision to use percentiles to define our cut-points is consistent with other 
studies that have utilized our resilience, general anxiety, and perceived stress measures, 
and a cut-point of 10 has been used to classify participants as having low partner support, 
results from our sensitivity analysis indicate that our findings are sensitive to our chosen 
cut-points.5,47–50 This may have prevented us from gaining meaningful insights into how 
best to identity and target treatments for women with lower levels of each adverse factor.  
2.5 CONCLUSION 
Adverse psychosocial factors including mental health symptoms, stress, and low 
psychosocial resources have been associated with an increased risk of preterm delivery, 
both individually and in aggregate. By identifying groups of women who experience 
different combinations of these adverse factors, we were able to gain information about 
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which factors may be most prevalent among different groups of women.
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3.6 TABLES 
Table 3.1: Distribution of psychometric measure scores in SPEC 
  Score distribution in SPEC 
Measure Score range Minimum 
10th 
percentile 
25th 
percentile 
50th 
percentile 
75th 
percentile 
90th 
percentile Maximum 
Depressive symptoms 0-30 0 0 2 4 8 12 27 
General anxiety 10-40 10 11 13 16 20 23 38 
Pregnancy-related 
anxiety 7-28 7 8 10 13 16 21 28 
Perceived stress 0-16 0 6 7 8 9 10 13 
Recent experience of 
stressful life events 0-11 0 0 0 1 2 5 11 
Resilience 0-100 0 57 66 76 86 94 100 
Friend and family 
support 0-15 0 9 11 14 15 15 15 
Partner support 0-15 0 10 12 14 15 15 15 
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Table 3.2: Baseline characteristics of 704 participants in the SPEC study (2014-2018) 
 
Overall 
n=704 
Age at enrollment (years) 33.2 (30.3, 36.3) 
Gravidity 2.0 (1.0, 3.0) 
Parity 1.0 (0.0, 1.0) 
Race/ethnicity  
Non-Hispanic white 402 (57.1) 
Non-Hispanic black 62 (8.8) 
Asian 71 (10.1) 
Hispanic 62 (8.8) 
Other 70 (9.9) 
Partnership status  
Married or living with partner 625 (88.8) 
Never married 61 (8.7) 
Divorced/separated 18 (2.6) 
Current smoker 96 (13.6) 
History of preterm birtha 88 (20.5) 
Education  
High school diploma or less  74 (10.5) 
Some college or associate’s degree 116 (16.5) 
Bachelor’s degree or higher 516 (73.3) 
Employment status  
Employed full-time 464 (65.9) 
Employed part-time 104 (14.8) 
Not employed 135 (19.2) 
Current student 464 (65.9) 
Annual household income  
<$25,000 118 (16.8) 
$25,000-$49,999 62 (8.8) 
$50,000-$74,999 68 (9.7) 
$75,000-$99,999 96 (13.6) 
³$100,000 360 (51.1) 
Experienced symptoms of depression or 
anxiety prior to current pregnancy  
223 (31.7) 
Clinical diagnosis of depression or anxiety 
prior to current pregnancy  
199 (28.3) 
Took medications for depression or anxiety 
prior to current pregnancy 
208 (29.5) 
Data presented as median (interquartile range) or n (proportion)  
a Restricted to 430 women who reported a prior delivery 
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Table 3.3: Fit indices for latent class analysis of adverse psychosocial factors 
Model Class 2 Class 3 Class 4 Class 5 
AIC 3701.3 3682.0 3675.2 3673.9 
BIC 3778.8 3800.5 3834.6 3874.4 
Sample-size adjusted BIC 3724.8 3717.9 3723.5 3734.7 
LMR-A 319.7 36.7 24.4 19.1 
P-value 0.00 0.16 0.30 0.21 
Entropy 0.82 0.73 0.77 0.79 
Abbreviations: AIC=Akaike information criterion, BIC=Bayesian information criterion, LMR-A=Lo- 
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Table 3.4: Conditional probabilities of latent class membership for three-class model 
 Class 1 Class 2 Class 3 
 Few adverse 
psychosocial factors 
Some adverse 
psychosocial factors 
Many adverse 
psychosocial factors 
n (%) 539 (76.6) 143 (20.3) 22 (3.1) 
Depressive symptoms    
No probable depression (<13) 99.8 79.5 8.3 
Probable depression (≥13) 0.2 20.5 91.7 
General anxiety    
Moderate/low symptomology (<90th percentile) 99.7 60.8 2.9 
High symptomology (≥90th percentile) 0.3 39.2 97.1 
Pregnancy-related anxiety    
Moderate/low symptomology (<90th percentile) 93.8 78.2 48.3 
High symptomology (≥90th percentile) 6.2 21.8 51.7 
Perceived stress    
Moderate/low symptomology (<90th percentile) 81.9 74.0 40.3 
High symptomology (≥90th percentile) 18.1 26.0 69.3 
Recent experience of stressful life events    
0-4 events (<90th percentile) 95.0 82.3 28.9 
5 or more events (≥90th percentile) 5.0 17.7 71.1 
Resilience    
Moderate/high (>10th percentile) 98.0 74.8 27.9 
Low (≤10th percentile) 2.0 25.2 72.1 
Partner support    
Moderate/high (>10th percentile) 97.0 79.5 41.0 
Low (≤10th percentile) 3.0 20.5 59.0 
Friend and family support    
Moderate/high (>10th percentile) 95.9 79.4 44.7 
Low (≤10th percentile) 4.1 20.6 55.3 
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Table 3.5: Conditional probabilities of latent class membership for two-class model 
 Class 1 Class 2 
 Few adverse 
psychosocial factors 
Some adverse 
psychosocial factors 
Proportion of sample 86.5 13.5 
Depressive symptoms   
No probable depression (<13) 98.6 53.1 
Probable depression (≥13) 1.3 46.9 
General anxiety   
Moderate/low symptomology (<90th percentile) 96.6 31.7 
High symptomology (≥90th percentile) 3.4 68.3 
Pregnancy-related anxiety     
Moderate/low symptomology (<90th percentile) 92.4 65.6 
High symptomology (≥90th percentile) 7.6 34.4 
Perceived stress   
Moderate/low symptomology (<90th percentile) 81.5 62.6 
High symptomology (≥90th percentile) 18.5 37.4 
Recent experience of stressful life events   
0-4 events (<90th percentile) 93.8 66.3 
5 or more events (≥90th percentile) 6.2 33.7 
Resilience   
Moderate/high (>10th percentile) 95.5 58.0 
Low (≤10th percentile) 4.5 42.0 
Partner support   
Moderate/high (>10th percentile) 95.0 66.4 
Low (≤10th percentile) 5.0 33.6 
Friend and family support   
Moderate/high (>10th percentile) 94.3 66.3 
Low (≤10th percentile) 5.7 33.7 
 
  
62 
 
Table 3.6: Demographic, socioeconomic, and psychological characteristics by latent class  
 Class 1 Class 2 Class 3 
 
Few adverse 
psychosocial 
factors 
Some adverse 
psychosocial 
factors 
Many adverse 
psychosocial 
factors 
Age at enrollment (years) 33.3 (30.7, 36.2) 32.3 (28.4, 36.6) 32.5 (26.6, 34.7) 
Gravidity 2.0 (1.0, 3.0) 2.0 (1.0, 3.0) 3.0 (1.2, 4.8) 
Parity 1.0 (0.0, 1.0) 1.0 (0.0, 1.0) 0.5 (0.0, 1.8) 
Race/ethnicity    
Non-Hispanic white 304 (58.1) 91 (55.8) 7 (38.9) 
Non-Hispanic black 67 (12.8) 29 (17.8) 3 (16.7) 
Asian 56 (10.7) 14 (8.6) 1 (5.6) 
Hispanic 47 (9.0) 11 (6.7) 4 (22.2) 
Other 49 (9.4) 18 (11.0) 3 (16.7) 
Partnership status    
Married or living with partner 485 (92.7) 130 (79.8) 10 (55.6) 
Never married 26 (5.0) 29 (17.8) 6 (33.3) 
Divorced/separated 12 (2.3) 4 (2.5) 2 (11.1) 
Current smoker 7 (1.3) 10 (6.1) 3 (16.7) 
History of preterm birth1 63 (19.7) 23 (13.2) 2 (18.2) 
Education    
High school diploma or less  42 (8.0) 26 (16.0) 5 (27.8) 
Some college or associate’s 
degree 76 (14.5) 36 (22.1) 3 (16.7) 
Bachelor’s degree or higher 405 (77.4) 101 (62.0) 10 (55.6) 
Employment status    
Employed full-time 361 (69.0) 92 (56.4) 11 (61.1) 
Employed part-time 79 (15.1) 24 (14.7) 2 (11.1) 
Not employed 83 (15.9) 47 (28.8) 5 (27.8) 
Current student 56 (10.7) 35 (21.5) 5 (27.8) 
Annual household income    
<$25,000 63 (12.0) 45 (27.6) 10 (55.6) 
$25,000-$49,999 42 (8.0) 16 (9.8) 4 (22.2) 
$50,000-$74,999 40 (7.6) 25 (15.3) 3 (16.7) 
$75,000-$99,999 79 (15.1) 16 (9.8) 1 (5.6) 
³$100,000 299 (57.2) 61 (37.4) 0 (0.0) 
Experienced symptoms of 
depression or anxiety prior to 
current pregnancy  
124 (23.7) 83 (50.9) 16 (88.9) 
Clinical diagnosis of depression or 
anxiety prior to current pregnancy  112 (21.4) 74 (45.4) 13 (72.2) 
Took medications for depression or 
anxiety prior to current pregnancy 124 (23.7) 72 (44.2) 12 (66.7) 
1 Restricted to participants who reported a prior delivery
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Table 3.7: Mean difference in gestational age at delivery and risk of preterm delivery by latent classes and individual adverse 
psychosocial factors 
 Mean difference (95% CI) Risk Ratio (95% CI) 
Adverse psychosocial factor latent classes   
Few adverse psychosocial factors REF REF 
Some adverse psychosocial factors -0.17 (-0.76, 0.43) 1.50 (0.86, 2.62) 
Many adverse psychosocial factors -0.63 (-3.67, 2.43) 1.29 (0.36, 5.00) 
Probable depression (vs. no probable depression) -0.45 (-1.39, 0.49) 1.72 (0.84, 3.51) 
High general anxiety (vs. moderate/low) 0.32 (-0.40, 1.03) 0.86 (0.40, 1.88) 
High pregnancy-related anxiety (vs. moderate/low) -0.21 (-0.87, 0.45) 1.17 (0.57, 2.42) 
High perceived stress (vs. moderate/low) -0.12 (-0.59, 0.35) 0.86 (0.45, 1.62) 
Recent experience of ≥ 5 stressful life events (vs. 0-4) -0.09 (-0.92, 0.74) 1.12 (0.52, 2.45) 
Low resilience (vs. moderate/high) -0.22 (-1.33, 0.88) 1.59 (0.82, 3.14) 
Low partner support (vs. moderate/high) -0.71 (-1.40, -0.01) 1.41 (0.69, 2.93) 
Low friend/family support (vs. moderate/high) -0.21 (-0.91, 0.48) 0.95 (0.41, 2.23) 
 
 
 
Table 3.8: Fit indices for the latent class analysis using psychometric measure scores at 75th percentile (anxiety and stress) and 25th 
percentile (low psychosocial resources) 
Model Class 2 Class 3 Class 4 Class 5 
AIC 6083.2 6051.6 6027.9 6018.0 
BIC 6160.6 6170.1 6187.4 6218.5 
Sample-size adjusted BIC 6106.6 6087.6 6072.9 6078.8 
LMR-A 437.0 48.7 41.1 29.0 
P-value 0.00 0.14 0.07 0.26 
Entropy 0.77 0.80 0.79 0.75 
Abbreviations: AIC=Akaike information criterion, BIC=Bayesian information criterion, LMR-A=Lo-Mendell-Rubin adjusted likelihood ratio 
test 
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Table 3.9: Conditional probabilities of latent class membership using psychometric measure scores at 75th percentile (anxiety and 
stress) and 25th percentile (low psychosocial resources) 
 Class 1 Class 2 Class 3 Class 4 
 High perceived stress 
Low social 
support 
High general anxiety 
and  low resilience 
High anxiety, high stress,  
low psychosocial resources 
n (%) 466 (66.2) 79 (11.2) 96 (13.6) 63 (8.9) 
Depressive symptoms     
No probable depression (<13) 99.0 99.3 99.4 41.6 
Probable depression (≥13) 1.0 0.7 0.6 58.4 
General anxiety     
Moderate/low symptomology (<75th 
percentile) 86.8 72.2 29.6 4.4 
High symptomology (≥75th percentile) 13.2 27.8 70.4 95.6 
Pregnancy-related anxiety         
Moderate/low symptomology (<75th 
percentile) 75.1 78.0 68.0 40.9 
High symptomology (≥75th percentile) 24.9 22.0 32.0 59.1 
Perceived stress     
Moderate/low symptomology (<75th 
percentile) 55.6 56.4 76.2 36.0 
High symptomology (≥75th percentile) 44.4 43.6 23.8 64.0 
Recent experience of stressful life events     
0-4 events (<75th percentile) 75.7 61.6 72.0 27.7 
5 or more events (≥75th percentile) 24.3 38.4 28.0 72.3 
Resilience     
Moderate/high (>75th percentile) 93.9 80.8 0.0 31.5 
Low (≤75th percentile) 6.1 19.2 100.0 68.5 
Partner support     
Moderate/high (>25th percentile) 93.8 28.0 60.4 39.3 
Low (≤25th percentile) 6.2 72.0 39.6 60.7 
Friend and family support     
Moderate/high (>25th percentile) 93.7 40.5 61.0 35.6 
Low (≤25th percentile) 6.3 59.5 39.0 64.4 
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Table 3.10: Fit indices for latent class analyses of adverse psychosocial factors among women in the first and second halves of 
pregnancy 
 First half of pregnancy 
n=464 
Second half of pregnancy 
n=240 
Model Class 2 Class 3 Class 4 Class 5 Class 2 Class 3 Class 4 Class 5 
AIC 2511.7 2506.8 2500.3 2501.3 1202.5 1201.2 1202.2 1207.5 
BIC 2582.2 2614.6 2645.5 2683.8 1261.3 1291.2 1323.4 1359.9 
Sample-size adjusted BIC 2528.3 2532.1 2534.4 2544.2 1207.4 1208.8 1212.5 1220.4 
LMR-A 218.1 32.7 24.0 17.7 98.4 15.3 16.8 0.85 
P-value 0.00 0.16 0.11 0.15 <0.001 0.38 0.30 13.8 
Entropy 0.85 0.75 0.83 0.87 0.76 0.84 0.87 0.29 
Abbreviations: AIC=Akaike information criterion, BIC=Bayesian information criterion, LMR-A=Lo-Mendell-Rubin adjusted likelihood ratio 
test 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
  
66 
 
Table 3.11: Conditional probabilities of latent class membership among women in the first and second halves of pregnancy 
 First half n=464 
Second half 
n=240 
 Class 1 Class 2 Class 3 Class 1 Class 2 Class 3 
 
Few adverse 
psychosocial 
factors 
Some adverse 
psychosocial 
factors 
Many adverse 
psychosocial 
factors 
Few adverse 
psychosocial 
factors 
Some adverse 
psychosocial 
factors 
Many adverse 
psychosocial 
factors 
n (%) 363 (78.3) 82 (17.6) 19 (4.1) 202 (84.2) 33 (13.8) 5 (2.1) 
Depressive symptoms       
No probable depression (<13) 99.8 80.2 2.6 99.9 83.0 63.9 
Probable depression (≥13) 0.2 19.8 97.4 0.1 17.0 35.9 
General anxiety       
Moderate/low symptomology 
(<90th percentile) 99.9 59.2 5.6 99.1 75.8 32.0 
High symptomology (≥90th 
percentile) 0.1 40.8 94.4 0.9 24.2 68.0 
Pregnancy-related anxiety       
Moderate/low symptomology 
(<90th percentile) 91.6 84.6 37.4 96.9 71.1 71.1 
High symptomology (≥90th 
percentile) 8.4 15.4 62.6 3.1 28.9 28.9 
Perceived stress       
Moderate/low symptomology 
(<90th percentile) 79.8 80.6 32.2 83.0 61.1 56.3 
High symptomology (≥90th 
percentile) 20.2 19.4 67.8 17.0 38.9 43.7 
Recent experience of stressful life 
events       
0-4 events (<90th percentile) 94.4 82.6 33.5 95.8 75.8 69.8 
5 or more events (≥90th 
percentile) 5.6 17.4 66.5 4.2 24.2 30.2 
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Resilience       
Moderate/high (>10th 
percentile) 97.5 74.0 40.6 83.0 79.5 75.8 
Low (≤10th percentile) 2.5 26.0 59.4 17.0 20.5 24.2 
Partner support       
Moderate/high (>10th 
percentile) 96.9 74.5 45.1 95.9 79.6 56.1 
Low (≤10th percentile) 3.1 25.5 54.9 4.1 20.4 43.9 
Friend and family support       
Moderate/high (>10th 
percentile) 95.6 83.6 49.9 96.9 82.8 48.4 
Low (≤10th percentile) 4.4 16.4 50.1 3.1 17.2 51.6 
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3.7 FIGURES  
Figure 3.1: Conceptual model of relationship between latent classes of adverse 
psychosocial factors and gestational age at delivery  
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4.0 PREGNANCY OUTCOMES FOLLOWING PREIMPLANTATION GENETIC 
TESTING FOR ANEUPLOIDY 
 
4.1 INTRODUCTION 
Despite many advances in in vitro fertilization (IVF) technology over the past four 
decades, only 27-45% of IVF cycles among women aged 18-40 years result in 
pregnancy.1 Chromosomal nondisjunction is thought to be a major contributor to low IVF 
success rates as it can cause nonviable aneuploid embryos that are naturally rejected by 
the body.2,3 To increase the probability of pregnancy and live birth among women 
undergoing IVF, preimplantation genetic testing for aneuploidy (PGT-A) was developed 
to identify euploid embryos prior to implantation.2–4 Once identified, only euploid 
embryos are transferred. 
 
PGT-A is an expensive and invasive technology, thus understanding which women are 
most likely to benefit from its use in their IVF treatment is critical. PGT-A may be 
particularly beneficial for women at higher risk of producing aneuploid embryos—such 
as older women or women with recurrent pregnancy loss. Results from studies comparing 
the incidence of live birth among women who did and did not use PGT-A are 
inconsistent.5,6 Conflicting results may be due to confounding by indication, as women 
whose embryos undergo PGT-A may be less likely to have a live birth due to factors such 
as advanced maternal age.  
 
Propensity score matching provides a means to analyze observational data with a 
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nonrandom treatment assignment by creating treatment groups that are balanced with 
respect to measured confounders.7 This approach can be helpful in situations where 
strong confounding by indication is expected (as in the case of PGT-A) as it isolates 
comparable exposed and unexposed participants for accurate estimation of the treatment 
effect.8,9  
 
The primary objective of this study was to evaluate the effect of using PGT-A on the 
incidence of live birth among women undergoing IVF, after controlling for confounding 
using a propensity score for PGT-A.  
 
4.2 METHODS 
4.2.1 Study design 
For this study we utilized clinical data from Boston IVF, an infertility clinic that treats 
couples from the Greater Boston, MA area. Boston IVF began using PGT-A in January 
2011. We included all women undergoing autologous IVF treatment, who had their first 
fresh oocyte retrieval from January 1, 2011 through October 31, 2017 (n=9,607). We 
excluded women without fertilized embryos from this oocyte retrieval (n=476), as they 
were not eligible for PGT-A. We also excluded women who had PGT-A performed on 
cryopreserved (rather than fresh) embryos (n=248), because the decision to utilize PGT-A 
for these women is based on different criteria, including having failed multiple IVF 
cycles. Additionally, we excluded women whose insurance only covered PGT-A after an 
unsuccessful fresh embryo transfer unless the patient had a history of multiple 
  
76 
miscarriages or was at risk of hyperstimulation, because we could not determine from our 
data which women met this exemption criteria (n=652). Finally, we excluded women 
whose embryos underwent preimplantation genetic testing for known familial mutations 
(n=4). Our final analytic cohort included 8,227 women. We included all thaw cycles 
associated with the first fresh oocyte retrieval in our analyses. Fresh and thaw cycles 
from subsequent oocyte retrievals were not included.  
4.2.2 Stimulation and transfer protocol  
All patients underwent ovarian stimulation, oocyte retrieval, and embryo transfers in 
accordance with standard protocols. The majority of patients were treated using a 
standard antagonist protocol, though agonist protocols also were used.2,10 Protocols were 
selected based on clinical judgement. Embryo transfers followed a standard protocol, and 
patients received vaginal or intramuscular progesterone for luteal support. 
 
The majority of fresh embryo transfers occurred three or five days after oocyte retrieval. 
All thaw cycles were performed after blastocyst vitrification on Day 5 or 6. A standard 
protocol (Irvine Scientific) was used for all thaw cycles. Frozen embryos were transferred 
on Day 5. 
 
4.2.3 PGT-A  
For patients undergoing PGT-A, a trophectoderm biopsy was performed on all good 
quality embryos (defined as an embryo between stages 3 and 6 with grade A or B inner or 
outer cell mass) from the first oocyte retrieval. A single genetics laboratory analyzed and 
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interpreted 90% of biopsies. Embryos were deemed euploid or aneuploid, and embryonic 
mosaicism data were not reported. During the study period, 1.5% of embryos had 
complex aneuploidies and 7.6% had whole deletions and duplications.  
Confirmed euploid embryos were transferred during subsequent thaw cycles, using 
protocols identical to those for patients undergoing thaw cycles with non-biopsied 
embryos. Aneuploid embryos were not transferred. 
 
4.2.4 Outcomes 
Our primary outcome of interest was live birth. Secondary outcomes of interest included 
number of embryos transferred, and the cumulative incidence of clinical pregnancies, 
ectopic pregnancies, miscarriages, therapeutic abortions, and stillbirths. Data on embryo 
transfers and clinical pregnancies were recorded in the patients’ medical records during 
their IVF treatment. After a clinical pregnancy was achieved, patients were referred to an 
obstetric provider. Boston IVF staff contacted all patients who achieved a clinical 
pregnancy within one month of their expected delivery to collect pregnancy outcome 
data.  
 
4.2.5 Propensity score variables 
We included demographic and clinical factors available to the IVF provider prior to PGT-
A or fresh embryo transfer in our propensity score model. We selected these variables 
based on a review of the literature and use of a directed acyclic graph (Figure 4.1). These 
variables included age at cycle start, body mass index (kg/m2), day 3 follicle stimulating 
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hormone (FSH), insurance status (self-pay vs. private), gravidity, parity, and indication 
for infertility treatment (endometriosis, male factor, other infertility, ovulation disorders, 
tubal disorders, unexplained infertility, uterine disorders) in the propensity score model. 
Although we also identified anti-Mullerian hormone levels, progesterone levels, estrogen 
levels, and prior infertility treatment as potential confounders, these variables were not 
available (prior infertility treatment) or had too much missing data (>50%) to be included 
in our analyses (anti-Mullerian hormone levels, progesterone levels, estrogen levels).   
 
4.2.6 Statistical analyses 
We had complete data on PGT-A utilization and cycle outcomes (embryo transfer, 
clinical pregnancy). We used multiple imputation to impute missing pregnancy outcome 
data (miscarriage, therapeutic abortion, live birth, stillbirth), which was missing for 
0.09% of women. We also imputed data for all pre-treatment demographic and clinical 
variables included in the propensity score model, as these data were available to the IVF 
provider when they recommended PGT-A to patients. Data missingness for variables 
included in the propensity score ranged from 0.0% (age) to 37.9% (Day 3 FSH). To 
improve prediction, we also included anti-Mullerian hormone, progesterone, and estrogen 
levels in the imputation model. We generated five imputation data sets using a Markov 
chain Monte Carlo method.11  
 
We used multivariable logistic regression models to estimate propensity scores for PGT-
A in each of the imputed datasets. We averaged the propensity scores across the datasets 
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prior to matching.12 We used the propensity score to match women who utilized PGT-A 
with women who did not in a 1:1 ratio. We used nearest neighbor matching with a caliper 
of 0.02 (0.2 of the standard deviation of the logit of the propensity score (0.1))13 (using 
the Pharmacoepidemiology Toolbox version 2.4.15, http://www.drugepi.org to do the 
matching).14  Women who were not matched were excluded from the analyses (Table 
4.1).  
 
As the risk of aneuploidy increases with age,  PGT-A may be more beneficial for older 
women. We conducted an age-stratified analysis to determine if the effect of PGT-A on 
live birth may be modified by age.15,16 We used multivariable logistic regression to 
calculate propensity scores for PGT-A, among women <35, 35-37, and ≥38 years old. 
These age categories are consistent with those used by the Society for Assisted 
Reproductive Technology.17 We averaged the propensity scores across each of the 
imputed datasets and matched women in a 1:1 ratio using nearest neighbor matching. The 
standard deviations of the logit for the propensity scores were 0.1 for both women aged 
<35 and 35-37 yielding calipers of 0.02 for both groups. The standard deviation of the 
logit among women ≥38 was 0.2 yielding a caliper of 0.04. 
 
We calculated standardized differences (difference in means or proportions divided by 
the pooled standard deviation) to compare post-matching covariate balance. Standardized 
differences are preferable to standard statistical tests for differences, because they are not 
influenced by sample size.18 Although there is not a standard threshold for imbalance, a 
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standardized difference of <0.1 typically is considered indicative of a negligible 
difference between groups in the mean or prevalence of a covariate.19,20  
 
We used log-binomial regression to calculate risk ratios (RR) and 95% confidence 
intervals (CI) comparing the cumulative incidence of outcomes of interest among patients 
who used PGT-A with those who did not.  
 
This study was approved by the institutional review board at Beth Israel Deaconess 
Medical Center. 
 
4.3 RESULTS 
Of the 8,227 women who had their first oocyte retrieval at Boston IVF during our study 
period, 1,108 (13.5%) utilized PGT-A. These women were slightly older than women 
who did not use PGT-A (Table 4.2). They were more likely to undergo IVF treatment due 
to other infertility (50.1% vs. 8.3%) than women who did not use PGT-A. In contrast, 
women who did not use PGT-A were more likely to undergo IVF for unexplained 
infertility, ovulation disorders, and male-factor infertility. Matching on propensity score 
resulted in good balance for all covariates (Table 4.3, Figure 4.2). 
 
The median (interquartile range) number of cycles among women who used PGT-A was 
2.0 IQR: (1.0, 2.0), while the median was 1.0 cycle (IQR: 1.0, 1.0) for women who did 
not use PGT-A (Table 4.4). Women who used PGT-A were 22% less likely to have at 
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least one cycle with an embryo transfer (RR: 0.78; 95% 0.73, 0.82) compared with 
women who did not use PGT-A (Figure 4.3). They were, however, more likely to have at 
least one cycle that resulted in a clinical pregnancy (RR: 1.15; 95% CI: 1.04, 1.28). 
Women who used PGT-A were 21% (RR: 1.21; 95% CI: 1.08, 1.35) more likely to have 
a cycle that resulted in live birth and 33% (RR: 0.67; 95% CI: 0.47, 0.95) less likely to 
have a cycle that resulted in miscarriage than women who did not use PGT-A. The 
median number of cycles among women who had a live birth was 2.0 (2.0, 2.0) for 
women who used PGT-A and 1.0 (1.0, 2.0) for women who did not use PGT-A.  
 
When we stratified by age, we observed that PGT-A was most beneficial for women ≥38 
years old (Table 4.5). Among women ≥38 years old (n=878), those who used PGT-A 
were 28% (RR: 1.28; 95% CI: 1.04, 1.56) more likely to achieve a clinical pregnancy and 
67% (RR: 1.67; 95% CI: 1.31, 2.13) more likely to have a live birth compared to women 
who did not use PGT-A (Figure 4.3). Among women aged 35-37 (n=540) those who used 
PGT-A were also more likely to achieve a clinical pregnancy (RR: 1.18; 95% CI: 0.99, 
1.40) and have a live birth (RR: 1.27; 95% CI: 1.05, 1.54) than women who did not use 
PGT-A. Although the effect estimates were imprecise, women <35 years old (n=582) 
who used PGT-A were slightly less likely to achieve a clinical pregnancy (RR: 0.94; 95% 
CI: 0.82, 1.07) and have a live birth (RR: 0.91; 95% CI: 0.78, 1.06) than women <35 
years old who did not use PGT-A. 
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4.4 DISCUSSION 
After controlling for confounding by propensity score matching, we found that women 35 
years old and older who utilized PGT-A were more likely to have at least one IVF cycle 
result in a clinical pregnancy and a live birth. Among women 35-37, those who used 
PGT-A were 18% more likely to achieve a clinical pregnancy, 35% less likely to have a 
miscarriage, and 27% more likely to have a live birth compared with women 35-37 years 
old who did not use PGT-A. Among women ≥38 years old, those who used PGT-A were 
28% more likely to achieve a clinical pregnancy, 56% less likely to have a miscarriage, 
and 67% more likely to have a live birth compared to women ≥38 years old who did not 
use PGT-A. We did not observe a benefit for using PGT-A among women younger than 
35.   
 
Our study suggests that PGT-A may only be beneficial for women over the age of 35. 
These findings are consistent with those from two recent randomized controlled trials. In 
the first study, investigators found that among women ≥38 years old, PGT-A users were 
twice as likely as non-users to have a live birth (52.9% vs 24.2%).6 Although 
investigators in the second study did not examine live birth rates, they did find that older 
women who used PGT-A had higher ongoing pregnancy rates (pregnancy >20 weeks) 
than women who did not use PGT-A (50.8% vs. 37.2%).21 In agreement with studies that 
have examined success of PGT-A among younger women, our findings suggest that 
PGT-A may not be beneficial for this population.22,23  
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Propensity score matching is advantageous when the goal is to estimate the effect of the 
treatment on the treated, because it isolates comparable exposed and unexposed subjects. 
In the process of creating this comparable population, however, many unexposed subjects 
are often discarded.24 This was the case in our study. Unmatched women who did not use 
PGT-A tended to be younger and were much more likely to undergo IVF for unexplained 
infertility, than matched women who did not use PGT-A (see Table 4.1). Additionally, 
we were unable to find matches for 9.2% of women who used PGT-A. However, as the 
cumulative incidence of our outcomes was similar between matched and unmatched 
women who utilized PGT-A, we do not believe our ability to estimate the effect of the 
treatment on the treated was limited by this exclusion.  
 
While we were able to include many of the primary predictors of IVF success in our 
propensity score model, our reliance on medical record data limited our ability to include 
several variables of interest (such as anti-Mullerian hormone levels and prior IVF 
treatment) as these could not be abstracted from patients’ records. Thus, our findings may 
be subject to residual confounding. Additionally, while many patients and providers may 
be interested in the cumulative live birth rate (the number of cycles needed to achieve a 
live birth), we were unable to estimate this measure as we only included cycles from the 
first oocyte retrieval in our analysis and the majority of patients who did not use PGT-A 
only had one IVF cycle.  
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4.5 CONCLUSION 
PGT-A is an expensive and invasive technology, making it important to understand 
which patients are most likely to benefit from its use in their IVF treatment. Our study 
suggests that PGT-A may not be beneficial for all women younger than 35. For older 
women, however, PGT-A may substantially increase the likelihood of achieving a 
clinical pregnancy and having a live birth. 
  
85 
4.6 TABLES 
Table 4.1: Demographic and clinical characteristics, and cycle and pregnancy outcomes among matched and unmatched women 
who utilized PGT-A  
 Non PGT-A PGT-A 
 
Matched 
n=1,015 
Unmatched 
n=6,104 
Matched 
n=1,015 
Unmatched 
n=93 
Demographic and clinical characteristics     
Age, years  37.5 (34.2, 40.5) 35.1 (32.0, 38.5) 37.3 (34.2, 40.0) 38.5 (37.1, 40.6) 
Body mass index, kg/m2 24.6 (22.0, 27.8) 25.9 (22.5, 29.0) 24.6 (21.9, 27.4) 24.0 (21.2, 26.7) 
Gravidity  1.0 (0.0, 2.0) 0.0 (0.0, 1.0) 1.0 [0.0, 2.0) 2.0 (1.0, 4.0) 
Parity  0.0 (0.0, 1.0) 0.0 (0.0, 0.0) 0.0 [0.0, 1.0) 0.0 (0.0, 1.0) 
Private insurance 979 (96.5) 5,995 (98.2) 976 (96.2) 88 (94.6) 
Cycle-day 3 follicle stimulating hormone  7.2 (5.8, 8.9) 7.0 (5.8, 8.6) 7.0 (5.9, 8.5) 7.0 (6.1, 8.0) 
Indication for ART     
Endometriosis 22 (2.2) 253 (4.1) 20 (2.0) 0 (0.0) 
Male factor 198 (19.5) 1,488 (24.4) 177 (17.4) 0 (0.0) 
Other 461 (45.4) 130 (2.1) 462 (45.5) 93 (100.0) 
Ovulation disorders 224 (22.1) 1,569 (25.7) 229 (22.6) 0 (0.0) 
Tubal disorders 46 (4.5) 455 (7.5) 49 (4.8) 0 (0.0) 
Unexplained infertility 51 (5.0) 2,106 (34.5) 65 (6.4) 0 (0.0) 
Uterine disorders 13 (1.3) 103 (1.7) 13 (1.3) 0 (0.0) 
Indication for PGT-A     
Advanced maternal age - - 524 (51.6) 44 (47.3) 
Recurrent implantation failure - - 31 (3.1) 0 (0.0) 
Recurrent miscarriage - - 247 (24.3) 41 (44.1) 
Other - - 213 (21.0) 8 (8.6) 
Cycle and pregnancy outcomes     
Embryo transfer 823 (81.1) 5,787 (94.8) 638 (62.9) 45 (48.4) 
Clinical pregnancy 404 (39.8) 3,243 (53.1) 465 (45.8) 39 (42.0) 
Ectopic pregnancy 8 (0.8) 67 (1.1) 4 (0.4) 0 (0.0) 
Miscarriage  63 (6.2) 510 (8.4) 49 (4.8) 4 (4.3) 
Therapeutic abortion 1 (0.1) 32 (0.5) 2 (0.2) 0 (0.0) 
Live birth 349 (34.4) 2,807 (46.0) 423 (41.7) 36 (38.7) 
Still birth 1 (0.1) 5 (0.1) 0 (0.0) 0 (0.0) 
Data presented as median (interquartile range) or n (%) 
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Table 4.2: Demographic and clinical characteristics among unmatched and propensity score matched women 
 Unmatched Matched 
 Non-PGT-A 
n=7,119 
PGT-A 
n=1,108 
Non-PGT-A 
n=1,015 
PGT-A 
n=1,015 
Age, years  35.4 (32.2, 38.9) 37.5 (34.3, 40.1) 37.3 (34.2, 40.5) 37.3 (34.2, 40.0) 
Body mass index, kg/m2 25.7 (22.3, 28.9) 24.4 (21.8, 27.3) 24.6 (22.0, 27.8) 24.6 (22.0, 27.8) 
Gravidity  0.0 (0.0, 1.0) 1.0 (0.0, 2.0) 1.0 (0.0, 2.0) 1.0 (0.0, 2.0) 
Parity  0.0 (0.0, 0.0) 0.0 (0.0, 1.0) 0.0 (0.0, 1.0) 0.0 (0.0, 1.0) 
Private insurance 6,975 (98.0) 1,071 (96.7) 979 (96.5) 976 (96.2) 
Cycle-day 3 follicle stimulating hormone  7.0 (5.8, 8.7) 7.0 (5.9, 8.5) 7.2 (5.8, 8.9) 7.0 (5.9, 8.5) 
Indication for ART     
Endometriosis 275 (3.9) 20 (1.8) 22 (2.2) 20 (2.0) 
Male-factor infertility 1686 (23.7) 177 (16.0) 198 (19.5) 177 (17.4) 
Other 591 (8.3) 555 (50.1) 461 (45.4) 462 (45.5) 
Ovulation disorders 1793 (25.2) 229 (20.7) 224 (22.1) 229 (22.6) 
Tubal disorders 501 (7.0) 49 (4.4) 46 (4.5) 49 (4.8) 
Unexplained infertility 2157 (30.3) 65 (5.9) 51 (5.0) 65 (6.4) 
Uterine disorders 116 (1.6) 13 (1.2) 13 (1.3) 13 (1.3) 
Indication for PGT-A     
Advanced maternal age - 568 (51.3) - 524 (51.6) 
Recurrent implantation failure - 31 (2.8) - 31 (3.1) 
Recurrent miscarriage - 288 (26.0) - 247 (24.3) 
Other - 221 (19.9) - 213 (21.0) 
Data presented as median (interquartile range) or % 
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Table 4.3: Standardized differences for covariates before and after matching 
 Unmatched Matched 
Age 0.37 -0.05 
Body mass index -0.21 -0.02 
Gravidity 0.44 0.03 
Parity 0.24 -0.01 
Day 3 FSH -0.03 -0.06 
Indication for ART 1.16 0.09 
Insurance -0.10 -0.03 
 
 
Table 4.4: Cycle and pregnancy outcomes stratified  
 
Non PGT-A 
n=1,015 
PGT-A 
n=1,015 
Embryo transfer 823 (81.1) 638 (62.9) 
Number of embryos transferred 2.0 (1.0, 3.0) 1.0 (1.0, 2.0) 
Clinical pregnancies 404 (39.8) 466 (45.9) 
Ectopic pregnancies 8 (0.8) 4 (0.4) 
Miscarriage 63 (6.2) 49 (4.8) 
Therapeutic abortion 1 (0.1) 2 (0.2) 
Live birth 349 (34.4) 423 (41.7) 
Stillbirth  1 (0.1) 0 (0.0) 
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Table 4.5: Cycle and pregnancy outcomes stratified by age 
 Age <35 35-37 Age ≥ 38 
 
Non-PGT-A 
n=291 
PGT-A 
n=291 
Non-PGT-A 
n=270 
PGT-A 
n=270 
Non-PGT-A 
n=439 
PGT-A 
n=439 
Embryo transfer 263 (90.4) 229 (78.7) 219 (81.1) 179 (66.3) 343 (78.1) 214 (48.7) 
Number of embryos transferred 1.0 (1.0, 2.0) 1.0 (1.0, 2.0) 2.0 (1.0, 2.0) 1.0 (1.0, 2.0) 2.0 (1.0, 3.0) 1.0 (1.0, 1.0) 
Clinical pregnancies 176 (60.5) 165 (56.7) 124 (45.9) 146 (54.1) 116 (26.4) 148 (33.7) 
Ectopic pregnancies 3 (1.0) 1 (0.3) 2 (0.7) 0 (0.0) 2 (0.5) 3 (0.7) 
Miscarriage 17 (5.8) 18 (6.2) 20 (7.4) 13 (4.8) 34 (7.7) 15 (3.4) 
Therapeutic abortion 1 (0.3) 1 (0.3) 1 (0.4) 1 (0.4) 2 (0.5) 0 (0.0) 
Live birth 164 (56.4) 149 (51.2) 107 (39.6) 136 (50.4) 80 (18.2) 133 (30.3) 
Stillbirth  3 (1.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
Data presented as median (interquartile range) or n (%) 
 
  
  
89 
4.7 FIGURES 
Figure 4.1: Directed acyclic graph 
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Figure 4.2: Propensity score frequency in a) unmatched and b) matched cohorts  
 
a) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
b) 
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Figure 4.3: Risk ratios (95% CI) for cycle and pregnancy outcomes, overall and age 
stratified 
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5.0 CONCLUSION 
5.1 STUDIES 1 AND 2 
Preterm delivery (delivery <37 weeks’ gestation) is a substantial problem in the United 
States.1 Thus, identification of modifiable risk factors for preterm delivery could have 
important implications for medicine and public health. Depression, anxiety and stress 
may increase the risk of preterm delivery by increasing placental corticotrophin-releasing 
hormone (CRH). CRH helps regulate the activity of the hypothalamic-pituitary-adrenal 
axis, and during pregnancy CRH also plays a central role in labor onset.2–4 In the first 
study of this dissertation, we evaluated the association of psychotropic medication use in 
pregnancy with gestational age at delivery, and the degree to which the association was 
confounded by severity of preconception depressive symptoms and perceived stress 
(measured before and during pregnancy). In the second study, we conducted a latent class 
analysis to identify groups of women who experienced similar combinations of mental 
health symptoms (depression and anxiety), stress, and low psychosocial resources 
(resilience and social support) and evaluated the risk of preterm delivery among the 
groups.  
 
In our first study, we found that women who used psychotropic medications during 
pregnancy had shorter gestations than women who were never treated with psychotropic 
medications. We observed this association among women with both high and low levels 
of preconception depressive symptoms and perceived stress, which was measured before 
and during pregnancy. In our second study, we identified three common clusters of 
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adverse psychosocial factors among pregnant women. Women with few adverse factors 
were most likely to have high perceived stress. Women with some adverse factors were 
more likely to have mental health symptoms, stress, and low psychosocial resources, with 
high general anxiety being the most prevalent factor. We also identified a class of women 
who experienced many factors. Compared to women with few adverse factors, women 
with some or many adverse psychosocial factors had shorter gestations and were more 
likely to deliver preterm. 
 
The two studies had several important limitations. In the first study, we collected data on 
depressive symptoms before pregnancy only. Therefore, we were not able to evaluate the 
association between depressive symptoms in pregnancy and gestational age at delivery. 
We believe any misclassification of depressive symptoms in pregnancy, however, is 
likely small as pre-pregnancy depression is a strong predictor of prenatal depression. 5–8 
Our results may also have been attenuated by immortal person-time bias if women who 
delivered early did not have the opportunity to be exposed to psychotropic medications. 
As almost all users of psychotropic medications during pregnancy used medications in 
the first and second trimesters, we think this is unlikely to be an appreciable source of 
bias. Finally, we were unable to evaluate the association between psychotropic 
medication use during pregnancy and preterm delivery sub-type (medically-indicated vs. 
spontaneous) due to the relatively small size of our cohort. 
 
We also may have been limited by the size of our cohort in our second study (n=704). 
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Our sample was also fairly homogenous, and it is possible that if our study were repeated 
in a larger, more diverse population, we may have observed more latent classes with 
different combinations of adverse psychosocial factors. Our second study was also 
limited by our dichotomization of continuous measures. We chose to dichotomize each 
measure in order to be able to identify groups of women with the highest (or lowest in the 
case of psychosocial resources) levels of our factors of interest. While this made each 
latent class more interpretable, we may have lost potentially meaningful information 
about the spectrum of symptom severity experienced by women in our cohort. Our 
sensitivity analysis also showed that our findings were sensitive to our chosen cut-points 
for each psychometric measure, which may have precluded us from gaining meaningful 
insights about women with lower levels of mental health symptoms, stress, and low 
psychosocial resources that may be useful for identification and treatment of these 
women.  
 
In our first study we found that although women who used psychotropic medications 
during pregnancy had slightly shorter gestations than women who never used 
psychotropic medication, the difference in gestational age between these two groups was 
small and not clinically significant. This suggests that psychotropic medications can be 
used to treat mental health symptoms and stress during pregnancy without increasing the 
risk of preterm delivery. Results from our second study suggest that pregnant women 
with many adverse psychosocial factors may benefit from treatment for mental health. 
We also found that these women are likely to have low social support; thus, they may 
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also benefit from group prenatal care or in-home counseling, as these interventions may 
increase social support while addressing mental health symptoms and stress.9,10 These 
findings, along with others from our study, suggest that by screening for multiple adverse 
factors, providers may gain valuable information to help tailor treatments.  
 
5.2 STUDY 3 
Although in vitro fertilization (IVF) technology has improved substantially over the past 
four decades, only 25-40% of IVF cycles among women aged 18-45 years result in 
pregnancy.11 These low pregnancy probabilities may be predominately due to transfer of 
aneuploid embryos, which the body naturally rejects.12,13 Preimplantation genetic testing 
for aneuploidy (PGT-A) was developed to increase the likelihood of achieving a 
pregnancy and live birth by identifying euploid embryos prior to implantation.12,13 In the 
third study of this dissertation we evaluated the effect of PGT-A on the incidence of live 
birth, after controlling for important confounders using a matched propensity score 
design. 
 
We found that PGT-A increased the probability of pregnancy and live birth among 
women at least 35 years of age. We did not observe a benefit for women younger than 35. 
These results are consistent with the fact that older women are more likely to produce 
aneuploid embryos.13,14   
 
This study was limited by our reliance on medical record data. We were unable to 
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abstract data on all potentially important confounders and therefore could not include 
them in our propensity score model. As a result, our findings may be subject to residual 
confounding. Additionally, we were unable to estimate the cumulative live birth rate (the 
number of cycles needed to achieve a live birth), because we only included cycles 
associated with the first oocyte retrieval and the majority of women who did not use 
PGT-A only had one IVF cycle from this retrieval.   
 
Similar to other studies of PGT-A, we found that PGT-A did not increase the likelihood 
of having a live birth among younger women.15,16  For women at least 35 years of age, 
however, PGT-A may increase the likelihood that they will achieve a live birth, 
suggesting that these women should consider using PGT-A as part of their IVF 
treatment.17,18  
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